GSAJumpPage

Understanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy
Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies#xD;
Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
A phase 1/2, open label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors
Phase I/II trial investigating the safety, tolerability, pharmacokinetics, immune and clinical activity of SX-682 in combination with TriAdeno vaccine regimen and M7824 (TGF-b “trap”/PD-L1; Bintrafusp alpha) in advanced solid tumors (STAT).
Phase II Trial of Olaparib (LYNPARZA) plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas that Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors.
Phase II Randomized Trial of Bethesda Protocol compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
Phase II Trial of Combination Immunotherapy in Subjects with Advanced Small Bowel and Colorectal Cancers
A Phase II Study of Bintrafusp alfa (M7824) in Checkpoint Inhibitor Naïve and Refractory Subjects with Urothelial Carcinoma
A first-in-human phase I single-agent dose-escalation, food effect and dose expansion study of oral ONC206 in recurrent and rare primary central nervous system neoplasms
A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19
A Pilot Study of E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer
Natural History Study of Children and Adults with Neuroendocrine Neoplasms (NENs)
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/refractory T-cell Malignancies
Natural History Study of Children and Adults with Adrenocortical Cancer
A Feasibility Study Investigating the Use of Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer Pain
Prospective Evaluation of High Resolution Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients with BAP1 Tumor Predisposition Syndrome#xD;
Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination with Anti-PD-L1/TGF-ß trap (M7824) in Subjects with HPV Positive Cancers
Biospecimen Procurement for Immunological Landscape Studies Following Hematopoietic Cell Transplantation
A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects with Thymoma and Thymic Carcinoma
A Phase I Study of E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia
Investigation of the B- and T-cell repertoire and immune response in patients with acute and resolved COVID-19 infection
A Phase I/II Study of the Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Advanced Pancreas Cancer.
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients with Primary Immunodeficiency Diseases
Phase 2 Trial of Encorafenib plus Binimetinib for Patients with BRAF V600E Mutated Relapsed/Refractory HCL
Phase 2 Trial for Binimetinib for Patients with Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
A Phase II Pilot Trial to Estimate Survival After A Non-Total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed with B-Acute Lymphoblastic Leukemia (ALL) Who are Pre-Allogeneic Hematopoietic Cell Transplantation (HCT)
Phase I/II of NHS-IL12 Monotherapy and in Combination with M7824 in Advanced Kaposi Sarcoma
A Phase II Feasibility Trial Using Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1b Trial of Sequential Combinations of BN-Brachyury, Entinostat, ado-trastuzuamb emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)
Phase I/II Trial of Combination Immunotherapy in Subjects with Advanced HPV Associated Malignancies
A Study of front line Ibrutinib for Newly Diagnosed Chronic Graft-versus-Host Disease
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-63898081 in Subjects with Advanced Stage Solid Tumors
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Genitourinary Malignancies Branch or Experimental Transplantation and Immunotherapy Branch Studies
Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Injuries
THREAD: A Phase I Trial of Trametinib and Hydroxychloroquine in Patients with Advanced Pancreatic Cancer
A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-ß trap (M7824 ) Alone and in Combination with TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma not associated with Human Papillomavirus Infection.
A Phase I study of TGF-ß trap (M7824) and NHS-IL12 (M9241) Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary Malignancies
First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects with Metastatic Solid Tumors
A Phase 1/2 open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients with prostate specific membrane antigen (PSMA) positive
Ex-Vivo Trial of En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Radium-223 in Biochemically Recurrent Prostate Cancer
A Phase I Clinical Trial of Selinexor (KPT-330) in Combination with Temozolomide and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma
Phase I/II trial of PLX038 (PEGylated SN38) and Rucaparib in Solid tumors and Small Cell Cancers
Radium-223 in Biochemically Recurrent Prostate Cancer
Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sézary Syndrome
Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC).
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer
T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell malignancies and Hodgkin Lymphoma
Avelumab (Bavencio) with IL-15 in subjects with clear-cell renal carcinoma
A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC).
Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients with Advanced Cancer
A Phase II Study Using the Administration of Autologous T-Cells Engineered using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic Cancer
Phase I/II Study of Lu-177-DOTATATE (Lutathera) in Combination with Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
A Phase 1/1b Study of Enhancement of Immune Reconstitution and Vaccine Responses with Administration of Recombinant Human IL-7-hyFc (NT-I7) in Older Subjects Following Chemotherapy
Incidental detection of maternal neoplasia through non-invasive cell-free DNA analysis (IDENTIFY), a natural history study
Development and Psychometric Testing of a Pediatric Chronic Graft- Versus-Host Disease (GVHD) Symptom Scale (PCSS)
Development and Psychometric Testing of a Pediatric Chronic GVHD Symptom Scale (PCSS)
A Phase II study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer
A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy with Oral Capecitabine for Gastric Adenocarcinoma with Peritoneal Carcinomatosis
A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination with tofacitinib in Persons with Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and other Mesothelin Expressing Solid Tumors
A Phase II Study of LMB-100 Followed by Pembrolizumab in the Treatment of Adults with Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase II Study of Oral Vancomycin in Patients with Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC)
A Phase II Study of E7 TCR T Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer
An Open-Label, Multicenter Rollover Study to Provide Continued Treatment with Anetumab Ravtansine For Participants with Solid Tumors Who Were Enrolled in Previous Bayer-Sponsored Studies.
A Phase 1 / 2 Single Arm Open-label Clinical Trial of TC-210 T-Cells in Patients with Advanced Mesothelin Expressing Cancer
A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell Lymphoma
Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies
A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas with Secondary Involvement of the Central Nervous System (CNS)
A Phase I Clinical Trial of T-cells Expressing an anti-SLAMF7 CAR for Treating Multiple Myeloma
Studying the biology of IDH-mutant gliomas via longitudinal observation of 2-hydroxyglutarate (2-HG) using MR spectroscopy
A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)
A Phase II Study of Immunotherapy with E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T cell Lymphoma
Natural History Study of Children and Adults with Chordoma
A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination with Pembrolizumab (KEYTRUDA) with Relapsed or Refractory Solid Tumors
A Phase II Pilot Study of Avelumab in Combination with Hypofractionated Radiotherapy in Patients with Relapsed Refractory Multiple Myeloma
A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
A Phase I Study of Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined with Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate Cancer
A Phase 2 Trial of The MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.
Long term follow-up of mesothelioma patients and their family members with germline mutations in BAP1 and other genes
A Phase I study of Moxetumomab Pasudotox-tdfk (Lumoxiti™) and Rituximab (Rituxan®) for Relapsed Hairy Cell Leukemia
Natural History Study of Men at High Genetic Risk for Prostate Cancer
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
An open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of a thorium-227 labeled antibody-chelator conjugate, BAY 2287411 Injection, in patients with solid tumors known to express
Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers
A Phase 2 Study of Response-Adapted Therapy with Copanlisib and Rituximab in Untreated Follicular Lymphoma #xD;
Tissue Acquisition and Genomics Analysis of Breast and Other Gynecologic Malignancies
A Phase II Study of Olaparib in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects
Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
A Natural History Study of Children and Adults with Fibrolamellar Hepatocellular Carcinoma
A Randomized Phase 2 Trial of Durvalumab (MEDI4736) with or without SBRT in Clinical Stage I, II, and IIIA Non-Small Cell Lung Cancer (NSCLC)
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Natural History and Biospecimen Accrual Study for Children and Adults with Rare Solid Tumors
Phase II Clinical Trial of Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma
Phase II trial evaluating Nivolumab in patients with IDH-mutant gliomas with and without hypermutator phenotype
A Phase II Study of M7824 in Subjects with Recurrent Respiratory Papillomatosis
Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-resistant Solid Tumors
A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior
Exploring Outcomes and Risk in Patients with Rare Central Nervous System Tumors
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma.
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
Phase II Study of the Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
Phase II Study Evaluating Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects with Hereditary Diffuse Gastric Cancer Syndrome
Phase II clinical trial of sunitinib in sarcomas of the central nervous system
PRISM: A Platform protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkinamp;#39;s Lymphoma
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
A Phase I Clinical Trial of T cells expressing a novel fully-human anti-BCMA CAR for treating multiple myeloma
An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1 with inoperable, progressive/symptomatic plexiform neurofibromas
A Phase 1/2 open-label, multi-center, safety and tolerability study of a single dose of 68Ga-PSMA-R2 in patients with biochemical relapse (BR) and metastatic prostate cancer (mPCa)
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers
A Phase I/II Trial in Patients with Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in which the Gene Encoding CISH was Inactivated Using the CRISPR/Cas9 System
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults with Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (cNF)
Phase II Study of Olaparib in Subjects with Malignant Mesothelioma
A Single Arm Pilot Study Combining CRLX101, a Nanoparticle Camptothecin, with Enzalutamide in Patients with Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
Pilot Study of Medication Adherence in Children, Adolescents, and Adults with Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials
Individual Patient Expanded Access Use of CV301 for the Treatment of Triple Positive Metastatic Breast Cancer
A Bioequivalence Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults with High Grade or High Risk Cancer and Their Caregivers
A Phase I/II Study of Immunotherapy Combination BN-Brachyury vaccine, M7824, ALT-803 and Epacadostat (QuEST1)
Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1)
A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Treatment of Patients with Castration Resistant Prostate Cancer using a Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors#xD;
A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 in Combination with SEL-110 in Subjects with Malignant Mesothelioma
An open-label Phase 1 trial to evaluate the safety and tolerability of a Modified Vaccinia Ankara (MVA) priming followed by fowlpox booster vaccines modified to express brachyury and T cell costimulatory molecules (MVA-BN-Brachyury/FPV-Brachyury)
A Phase IB/II Single-arm Study of M7824 (MSB0011359C) in Combination with Gemcitabine in Adults with Previously Treated Advanced Adenocarcinoma of the Pancreas
A Pilot Study to Evaluate the Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men with Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Phase II Trial of M7824 in Subjects with HPV Associated Malignancies
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients with Metastatic Cancer
Generation of Cancer Antigen-Specific T-Cells from Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential Future Therapy
Long Term Follow-up of Subjects Exposed to NY-ESO-1c259 T, a Genetically Engineered NY-ESO-1 Specific T Cell Receptor
A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Phase I Trial Using a Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy with Floxuridine and Dexamethasone in Combination with Systemic Chemotherapy for Patients with Colorectal Cancer Metastatic to the Liver
Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
Phase I Trial of 5-aza-4'-thio-2'-deoxycytidine (Aza-TdC) in Patients with Advanced Solid Tumors
Phase III randomized Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus Observation
Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Molecular Characterization of Viral-associated Tumors, Tumors occurring in the Setting of HIV or other Immune Disorders and Castleman Disease
CC-4047-BRN-001: A Phase 2 Clinical Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults with Recurrent or Progressive Primary Brain Tumors
A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
Phase Ib multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies
Phase IIB Study of Cediranib and Olaparib Combination in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Fallopian Tubal and/or Primary Peritoneal Cancer without Germline BRCA Mutation, Who Had Prior Bevacizumab (D8488C0001) #xD;
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicinium (oportuzumab monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with Bacillus Calmette-Guérin (BCG)
A Feasibility Study of Mobile Sensor Technologies to Assess General Symptomology of Cancer Patients
A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects with Relapsed/Refractory B-cell Malignancies
Phase I Trial of image guided focally dose escalated prostate SBRT for locally recurrent prostate cancer after prior radiotherapy
Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL),and Other Extranodal Diffuse Large B-cell Lymphomas#xD;
Assessing the Impact of Glioblastoma Multiforme on the Quality of Life of Patients and Caregivers (The GlioQoL Observational Study)
A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer harboring KRAS G12R Mutations
Phase I/II Evaluation of Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients with Inoperable or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and
Leukapheresis for CAR-Therapy Manufacturing
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 with Pembrolizumab in Adults with Previously-Treated Malignant Pleural Mesothelioma
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Phase 1b Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of PEN-866 in Advanced Solid Malignancies
A Phase I Study of Immunotherapy with E6 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
Phase I/II Study of T-DM1 alone versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
Prospective Study of Clonal Evolution in Follicular Lymphoma
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers
Collection of Malignant Ascites, Pleural Fluid and Blood from Patients with Solid Tumors
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Evaluation of 18F-DCFPyL PSMA- versus 18F-NaF-PET imaging for Detection of Metastatic Prostate Cancer
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), in Children and Adults with Wild Type GIST, Pheochromocytoma and Paraganglioma Associated with Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients with B7-H3-Expressing Relapsed or Refractory Solid Tumors
An Open-label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) inhibitor Selumetinib (AZD6244 hydrogen sulfate) in Patients with Neurofibromatosis Type 1 (NF1) related Gastrointestinal Stomal Tumors (GIST)
A Phase 2 Study of Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination with Capecitabine and Oxaliplatin (CAPOX) in Subjects with Advanced Biliary Tract Carcinoma (BTC)
Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer with Positive Peritoneal Cytology
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based Chemotherapy
Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
A Randomized Phase II trial of Standard of Care Alone or in Combination with Ad-CEA vaccine and Avelumab in Patients with Previously Untreated Metastatic or Unresectable Colorectal Cancer
Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor, alone or in combination with Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-Small Cell Lung Cancer
A Phase I/II Trial of the Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination with the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients with Embryonal and Alveolar Rhabdomyosarcoma
Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas including Anaplastic Large Cell Lymphomas
Prospective Evaluation and Molecular Profiling in Patients with Gastric Tumors
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
A Phase Ib Open Label, Dose Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination with M9241 (NHS-IL12) in Subjects with Locally Advanced, Unresectable, or Metastatic Solid Tumors
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Clinical Sequencing of Cancer and Tissue Repository: ClinOmics
A randomized, double blind phase II trial of Surgery, Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in newly diagnosed Glioblastoma (GBM)
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia
A Phase II Trial of CUDC-907 in Patients with Metastatic and Locally Advanced Thyroid Cancer
Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation
A Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy Subjects with Non-Small Cell Lung Cancer
A Phase I Study of a Combination of MM-398 and Veliparib in solid tumors
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) plus Temozolomide versus Temozolomide alone in Adults with Recurrent Anaplastic Astrocytoma and Glioblastoma
A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults with Metastatic Cancers
Phase I/II Study of PROSTVAC in Combination with Nivolumab in Men with Prostate Cancer
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
A Phase II Study of Avelumab in Subjects with Recurrent Respiratory Papillomatosis
Phase I/II Evaluation of Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients with Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms with Pleuropulmonary Metastases
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers
Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration
Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous System
Phase I Evaluation of Adjuvant Oral Decitabine and Tetrahydrouridine with or without Celecoxib in Patients Undergoing Pulmonary Metastasectomy
Phase II Trial with Safety Run-in of the Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects for the Expansion of T Cells for Adoptive Cell Therapy
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing Cancers
A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 with or without Nab-Paclitaxel (Abraxane) in Patients with Malignant Mesothelioma
A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
A Phase I/II Trial of CRLX101, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
An Open Label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination with Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 in Subjects with
Pilot Study of Ultrasound Guided Focal Thermal Ablation of Prostate Cancer
Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients with Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma
A Phase 1/2 study of baricitinib, a JAK1/2 inhibitor, in chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (SCT)
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal
An Open Label Phase 1B/2 Trial of TRC 105 and Sorafenib in Patients with Hepatocelluar Carcinoma (HCC)
A Phase I Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of a Vaccine-Based Immunotherapy Regimen (VBIR) for Prostate Cancer (PF-06753512)
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
Phase I Study of Pembrolizumab in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Biospecimen Procurement for Genitourinary Malignancies and Experimental Transplantation and Immunology Branch Immunotherapy Protocols
A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)
A Phase 1b/2 study of alvelestat (MPH966), an oral neutrophil elastase inhibitor, in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
Collection and Distribution of Blood Components from Healthy Donors for In Vitro Research Use
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy
Psychological Benefits of a Normalized Camping Experience for Children with Cancer
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer
Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients with Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence
Magnetic Resonance Imaging at 1.5 and 3.0 Tesla
Multidisciplinary Etiologic Study of Familial Testicular Cancer
Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study
Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome
Eligibility Screening and Tissue Procurement for the NIH Intramural Research Program Clinical Protocols
Follow-up for Patients Previously Enrolled on the Center for Cancer Research Protocols
DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction
Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors
A Phase II Trial in Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression
A Phase I Study of Single-agent AZD1775 (MK-1775), a Wee1 Inhibitor, in Patients with Advanced Refractory Solid Tumors
A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma
Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors#xD; #xD;
A Phase I Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults with Refractory Solid Tumors#xD;
Molecular Analysis for Therapy Choice (MATCH) (EAY131)
A Pilot Study of an Integrated Imaging Strategy to Phenotype Progression of Liver Tumors during and after Chemoembolization
Biomarkers in Acute Graft-Versus-Host Disease (GVHD) and Extracorporeal Photopheresis added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD
T Cells Expressing a Fully-human Anti- CD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
A Phase 1 Trial of Pomalidomide in Combination with Liposomal Doxorubicin in Patients with Advanced or Refractory Kaposi Sarcoma
A Phase II Study using LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors during Treatment with Transarterial Embolization (TAE) Alone or combined with Thermal Ablation
Docetaxel and PROSTVAC for Metastatic Castration Sensitive Prostate Cancer
Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events after Participation in Pediatric Oncology Branch Clinical Trials
A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Treatment of Children with Cancer
Prostvac in Patients with Biochemically Recurrent Prostate Cancer
A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophelia Cohort (HGDS-3)
A Prospective Randomized and Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
A Phase 1 Study of bb2121 in BCMA-expressing Multiple Myeloma
An Open-Label, Phase 1 Study of the Safety and Immunogenicity of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Subjects with Non-Small Cell Lung Cancer
Gut Microbiota in Patients with HCC
A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
A Phase I-II trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas
Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients with High-Risk and Recurrent Pediatric Sarcomas
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
Phase II trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi- Center Trial
Randomized Control Trial of Adrenalectomy versus Observation for Subclinical Hypercortisolism
A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
A Phase I/II Trial ofCrolibulin (EPC2407) plus Cisplatin in Adults with Solid Tumors with a Focus on Anaplastic Thyroid Cancer (ATC)
Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active Surveillance
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-Over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, in Patients with Recurrent Osteosarcoma Localized to the Lung
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals with Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination with Standard Chemotherapy in Patients with Advanced and/or Treatment-Refractory Solid
Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma
A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults with Refractory Solid Tumors
A Pilot Study of Metformin in Patients with a Diagnosis of Li-Fraumeni Syndrome
Electromagnetic Tracking of Devices During Interventional Procedures
A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy
Prospective Randomized Trial Comparing Navigation with Xperguide vsElectromagnetic Tracking vsConventional Methods during Percutaneous Image Guided Procedures
Imaging Review of Patients who have Undergone Imaging Studies in the Radiology and Imaging Sciences Department of the NIH Clinical Center
Fusion Guided Thermal Ablation Combined with External Beam Radiation for Hepatic Neoplasms
Prospective Randomized Multicenter Trial Comparing Navigation with 3D Roadmap vsConventional Angiography During Trans-arterial Embolization
Prospective Pilot Observational Study Examining Cone Beam CT and CT Thermometry During Ablations
Sonalleve MR-HIFU for Palliation of Bone Pain: Pilot Study
A Targeted Phase I/II trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade®), in Adults with Solid Tumors with a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects with B-cell Malignancies
A Pilot Study of Tc-94m Sestamibi PET MDR Imaging
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination with Trastuzumab in Breast Cancer Subjects with Brain Metastases
Phase II Trial of Depsipeptide (NSC 630176) in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-cell Lymphoma
A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients with Recurrent Brain Metastases#xD;
Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma
Collection of Blood, Fluid, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer or Normal Volunteers
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected
A Phase Ib, Dose Escalation, Multiple Dose Trial with HuMax-IL8 in Patients with Metastatic or Unresectable, Locally Advanced Malignant Solid Tumors
Phase I/II Trial of Yttrium-90-labeled Daclizumab (anti-CD25) Radioimmunotherapy with High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin's Lymphoma
A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults with Refractory Solid Tumors
A Phase I Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors
A Phase 2, open-label, single-arm, intra-subject dose-escalation study to investigate the biological activity, safety, tolerability, and pharmacokinetics of ponesimod in subjects with symptomatic moderate or severe chronic GVHD inadequately responding to
Phase I/II Trial of Vandetanib in Combination with Metformin in Subjects with HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Phase 2 Study of Everolimus Therapy in Patients with Birt-Hogg-Dubé Syndrome (BHD)-Associated Kidney Cancer
Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients with High-Risk and Recurrent Pediatric Sarcomas
A Phase I Trial of Pomalidomide for Children with Recurrent, Progressive or Refractory CNS Tumors
A Phase I/II Study of Flavopiridol in Relapsed or Refractory Mantle Cell Lymphoma (MCL) and Diffuse Large B-cell Lymphoma (DLBCL)
Phase II Study of Dose-Adjusted EPOCH +/-Rituximab in Adults with Untreated Burkitt Lymphoma, c-MYC+ Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma
Phase 1 Study of Ibrutinib and Immuno-chemotherapy using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs#xD;
A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan with Venous Filtration via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver
Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma
Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors
Retrospective Review of the Management of Malignant Peritoneal Mesothelioma
A Pilot Study of Imatinib Mesylate in Children and Adults with Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas with Botulinum Toxin
A Phase 2 Study of Anakinra in Inflammatory Pustular Dermatoses: Evaluation of Therapeutic Efficacy and Validation of Pathogenic Mechanisms
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
A Phase I Clinical Trial of T-cells Targeting B-cell Maturation Antigen for Previously Treated Multiple Myeloma
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in CAR T-Cell Studies
A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer
A Phase I Study of Dasatinib in Combination with Bevacizumab in Advanced Solid Tumors
Phase II Open Label Non-Randomized Single Agent Study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-Mimetic Birinapant (TL32711; NSC 756502) in Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal
Collection of Blood from Patients with Ovarian, Primary Peritoneal or Fallopian Tube Cancer
A Phase 1, Single Center, Dose-Escalation Study of SS1(dsFv)PE38 Administered Concurrently with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Epithelial Pleural Mesothelioma
Phase II Study of IMC-A12 in Patients with Mesothelioma who have been Previously Treated with Chemotherapy
A Pilot/ Phase II Study of Pentostatin Plus Cyclophosphamide Immune Depletion to Decrease Immunogenicity of SS1P in Patients with Mesothelioma, Lung Cancer or Pancreatic Cancer
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Antimesothelin Antibody Drug Conjugate BAY 94-9343 in Subjects with Advanced Solid Tumors#xD;
A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS 207 in Combination with Pemetrexed and Cisplatin as Front-line Therapy in Adults with Malignant Pleural Mesothelioma
Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing Cancers
Long-Term Follow-Up of Subjects who have Participated in Aduro-sponsored Protocols
Phase IA/IB, Open-Label, Multicenter, Multiple Ascending Dose Study Followed by an Extension Phase to Evaluate the Safety, Tolerability, Pharmacokinetics and Activity of RO6927005, an anti-Mesothelin (MSLN) Recombinant Cytolytic Fusion Protein (cFP),
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease#xD;
Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the
A Randomized Double-Blind Pilot Study of Topical Clobetasol 0.05% Oral rinse for Oral Chronic Graft-Versus-Host Disease
A Randomized Phase 2 Single-Center Study of Pomalidomide for Chronic GvHD
Collection of Saliva and/ or peripheral blood from Healthy Volunteers for Research
A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers
MR Image Guided Focal Therapy in Prostate Cancer
A Phase II Study of Neoadjuvant rFowlpox-PSA (L155)-TRICOM (Prostvac-F/TRICOM) in Combination with rVaccinia-PSA (L155)-TRICOM (Prostvac-V/TRICOM) in Men with Prostate Cancer Undergoing Treatment with Radical Prostatectomy
Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets
Phase II Study in Patients with Metastatic Ocular Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Autologous Tumor-Infiltrating Lymphocytes with or without High Dose Aldesleukin
Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine in Advanced Malignancies
A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine with Tetrahydrouridine (FdCyd + THU)
Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors
Phase I Trial of 4amp;#39;-thio-2amp;#39;-deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
A Phase II Study of BAY 43-9006 (Sorafenib) in Combination with Cetuximab (ErbituxTM) in EGFR Expressing Metastatic Colorectal Cancer (CRC)
Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients with Refractory Solid Tumors and Low-Grade Non-Hodgkinamp;#39;s Lymphoma
A Phase I and Pharmacokinetic Single-Agent Study of Romidepsin in Patients With Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors, and Varying Degrees of Liver Dysfunction
A Pilot Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
Effects of Antimicrobial Treatments on the Microbiome in Healthy Volunteers and Patients with Atopic Dermatitis
Studies of Dermatologic Diseases-Biospecimen Acquisition Protocol
A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC /TRICOM and Flutamide, vs. Flutamide Alone in Men with Androgen Insensitive, Non Metastatic (D0.5) Prostate Cancer
A Randomized Phase II Study of Tecemotide in Combination with Standard Androgen Deprivation Therapy and Radiation Therapy for Untreated, Intermediate and High Risk Prostate Cancer Patients
A Phase 2 Study of GI-6207 in Patients with Recurrent Medullary Thyroid Cancer
A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men with Metastatic Castration Resistant Prostate Cancer
A Phase II Trial of Enzalutamide in Combination with PSA-TRICOM in Patients with Non-Metastatic Castration Sensitive Prostate Cancer
A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients with Metastatic Castration Resistant Prostate Cancer Who Have Previously Been Treated with Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer
PET Imaging Of Renal Cell Carcinoma With 18F-VM4-037: A Phase II Pilot Study For Detection Of Disease And Correlation With VHL Mutation Status
Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
A Phase II Trial of IPH2101 (anti-KIR) in Smoldering Multiple Myeloma (SMM)
Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study
A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination with mTOR inhibitor RAD001 (Everolimus) in Patients with Relapsed Multiple Myeloma or Lymphoma
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Study
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study
A phase I study with an expansion cohort of the PARP inhibitor AZD2281 (KU-0059436) combined with carboplatin in breast and ovarian cancer in BRCA 1/2 mutation carriers (familial breast and ovarian cancer) and sporadic triple negative breast cancer and
A Pharmacokinetic/Pharmacodynamic Study with a Phase I Run-In with a PARP Inhibitor (Olaparib) in Combination with Carboplatin for Refractory or Recurrent Women's Cancers
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Long-Term Storage of Specimens of Subjects Previously Enrolled in Multiple Studies of the Women's Cancers Clinic
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer
A Phase 2 Pilot Study of BMN 673 (Talazoparib), an Oral PARP Inhibitor, in Patients with Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer who have had prior PARP Inhibitor Treatment
Phase I/II Study of the Anti-programmed Death Ligand-1 Antibody MEDI4736 in Combination with Olaparib or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults with B Cell Malignancies#xD;
Pilot Study of Tocilizumab in Patients with Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - associated Multicentric Castleman Disease
A Phase I/II Study of an Antitumor Vaccination Using Alpha(1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients with Refractory or Recurrent Non-Small Cell Lung Cancer
A Pilot Study of Sirolimus (Rapamycin, Rapammune®) in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN
Prospective analysis of genotypes in adults undergoing therapy for lung cancer #xD; #xD;
Multicenter Phase II Study of IMC-A12 in Patients with Thymoma and Thymic Carcinoma who have been Previously Treated with Chemotherapy#xD; #xD;
A Phase 2, Open Label Trial of Dacomitinib (PF-00299804) in Selected Patients with Advanced Adenocarcinoma of the Lung
Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF-02341066 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus
A Phase 1/2 Study of PXD101 (Belinostat) in Combination with Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic Malignancies#xD; #xD;
Phase II Study of Oral PHA-848125AC in Patients with Thymic Carcinoma Previously Treated with Chemotherapy
Randomized Phase II Study of AZD6244 (mitogen-activated protein kinase inhibitor) MEK-Inhibitor with erlotinib in KRAS wild type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 with erlotinib in mutant KRAS Advanced
Phase II Study of Oral PHA-848125AC in Patients with Malignant Thymoma Previously Treated with Multiple Lines of Chemotherapy
A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic Chemotherapy
A Phase 1, Open-label, Dose-escalation Study of SNX-5422 and Everolimus in Subjects with Neuroendocrine Tumors
A Phase 1 Study of AZD6244 in Combination with Cetuximab in Refractory Solid Tumors
A Multicenter Randomized Phase II Study of NPC-1C in Combination with Gemcitabine and nab-Paclitaxel versus Gemcitabine and nab-Paclitaxel Alone in Patients with Metastatic or Locally Advanced Pancreatic Cancer Previously Treated with FOLFIRINOX
A Pilot Study of Immune Checkpoint inhibition (Durvalumab with or without Tremelimumab) in Combination with Radiation Therapy in Patients with Unresectable Pancreatic Cancer
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults with Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin's Lymphoma (NHL)
Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo® (Vincristine Sulfate Liposomes Injection) in Children and Adolescents with Refractory Cancer
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation from Related or Matched Unrelated Donors in Pediatric Patients with Hematologic Malignancies
Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Phase I/II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Smoldering and Chronic Adult T-cell Leukemia (ATL)
Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 [(hetIL-15) (IL15 / sIL-15Ra)] alone and in combination with PDR001 in Adults with Metastatic Cancers
An Open Label Phase I Study to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)
A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination with Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma.
Evaluation of the Natural History and Management of Pancreatic Lesions Associated with Von Hippel-Lindau
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
A Phase II Trial of Valproic Acid in Patients with Advanced Thyroid Cancers of Follicular Origin
Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer
Evaluation of Diagnostic and Prognostic Molecular Markers in Adrenal Neoplasm
A Phase I/II Trial of IL-13-PE in Patients with Treatment Refractory Malignancies with a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma
Evaluation of 68Gallium- DOTATATE PET/CT for Detecting Primary and Metastatic Neuroendocrine Tumors
Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma
A Phase II Trial of Mutation-Targeted Therapy with Sunitinib or Everolimus in Patients with Advanced Low-or Intermediate Grade Neuroendocrine Tumors of the Gastrointestinal tract and Pancreas
Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
A Phase I/II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma (HCC)
Acquisition of Blood and Tumor Tissue Samples from Patients with Gastrointestinal Cancer
A Phase II Study of TRC105 in Patients with Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine (with Cyclophosphamide) Alone or Followed by CRS-207 in Adults with Metastatic Pancreatic Adenocarcinoma
A Phase I/II Study of ISIS 183750 in Combination with Irinotecan in Irinotecan-refractory Colorectal Cancer
A Pilot Study of Tremelimumab - A Monoclonal Antibody against CTLA-4 in combination with Trans-Arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA) or Cryoablation in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract
A Pilot Study of AMP-224, a PD-1 Inhibitor, in Combination with Stereotactic Body Radiation Therapy (SBRT) in Patients with Metastatic Colorectal Cancer
Phase 2 Study of MK-3475 in Patients with Microsatellite Unstable (MSI) Tumors
A Pilot Study of AZD9150, a STAT3 Antisense Oligonucleotide in Malignant Ascites
A Phase II Study of TRC105 in Adults with Advanced/Metastatic Urothelial Carcinoma
A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients with Metastatic Castrate-Resistant Prostate Cancer to Bone Treated with Either an Antimicrotubule Directed Agent or Androgen Receptor (AR)-Directed Therapy
A Phase II Study of Cabazitaxel in Patients with Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
A Phase I/II Trial of Topotecan with VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers
Pilot Study of Eovist® (Gadoxetate) Enhanced MRI for the Detection of Prostate Cancer
Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Metastases in Genitourinary (Prostate, Bladder and Kidney) Cancers
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies
Phase I/II Trial of PLX3397 in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Randomized Controlled Trial of Total Thyroidectomy with and without Prophylactic Central Neck Lymph Node Dissection in Patients with Low-risk Papillary Thyroid Cancer
A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer
The Melanoma Disease Management Program Psychosocial/ Behavioral/ Epidemiology/ Prevention Studies
Biomarkers and Histopathology of Merkel cell carcinoma
A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of MSB0010718C in Subjects with Merkel Cell Carcinoma
A Phase 1, Dose Escalation Study of MGAH22 (Fc-optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients with Refractory HER2 Positive Breast Cancer and Patients with Other HER2 Positive Carcinomas for Whom No Standard Therapy Is Available
Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
A Pilot Study of Inpatient Hospice with Procurement of Tissue on Expiration in Thoracic Malignancies
Tissue Procurement and Natural History Study of Patients with Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) given in combination with PANVAC versus BCG given alone in Adults with High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) who failed at least 1
Care of the Urothelial Cancer Patient and Prospective Collection of Biospecimens from Healthy Volunteers and Urothelial Cancer Patients
Evaluation of the Natural History of Patients with Tumors of the Central Nervous System
Expanded Access (Compassionate Use) Treatment Protocol with Rindopepimut (CDX-110)
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed Glioblastoma
A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived from Patients with Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen
Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing Human Thyroglobulin to Patients with Thyroglobulin Expressing Thyroid Cancer
A Phase I Study of Ipilimumab (Anti-CTLA4) in Children, Adolescents, and Young Adults with Treatment Refractory Cancer
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-Over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, in Patients with Recurrent Osteosarcoma Localized to the Lung
An Open-Label, Multicenter, Single-Arm, Phase I Dose-Escalation with Efficacy Tail Extension Study of RO5185426 in Pediatric Patients with Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Data Collection, Standard Care and Interventions in CCR, NCI
A Phase II Trial of Docetaxel, Thalidomide, Prednisone, and Bevacizumab in Patients with Androgen-Independent Prostate Cancer
A Phase 2 trial of Bevacizumab, Lenalidomide, Docetaxel and Prednisone(ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer
A Phase I and Randomized Phase II Multicenter Study of Cabozantinib (XL184) plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer
Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
Exceptional Responders Pilot Study: Molecular Profiling of Tumors from Cancer Patients who are Exceptional Responders
A Pilot Study of Vaccination with Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma
A Targeted Phase I/II trial of ZD6474 (Vandetanib CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade®), in Adults with Solid Tumors with a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
A Phase I/II Trial of Crolibulin (EPC2407) plus Cisplatin in Adults with Solid Tumors with a Focus on Anaplastic Thyroid Cancer (ATC)
Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma
A Randomized Trial of Filgrastim-SD/01 vs Filgrastim in Newly Diagnosed Children and Young Adults with Sarcomas Treated with Dose-Intensive Chemotherapy
Eligibility Screening and Tissue Procurement for the National Cancer Institute (NCI), Pediatric Oncology Branch (POB) Clinical Research Protocols
A Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) With or Without Interferon Gamma in Patients with Refractory Pediatric Solid Tumors
Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research-Network (CCRN) Childrenamp;#39;s Oncology Group
A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T cells in HLA-A2+ Patients with Synovial Sarcoma
A Phase I Trial of T Cells Expressing an anti-GD2 Chimeric Antigen Receptor in Children and Young Adults with GD2+ Solid Tumors
Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events after Participation in Pediatric Oncology Branch Clinical Trials
Phase I/II Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
A pilot study of autologous T-cell transplantation with vaccine driven expansion of anti-tumor effectors after cytoreductive therapy in metastatic pediatric sarcomas
Treatment of Children and Young Adults with Cancer or Rare Diseases
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients with Relapsed or Refractory Hairy Cell Leukemia (HCL)
Request to Conduct Research for Same Use of Stored Human Samples, Specimens, or Data Collected in a Terminated NCI-IRB Protocol. Protocol Numbers of Terminated Protocols: 96C0064; 99C0014; 98C0078; 94C0172; 03C0243; 01C0011; 09C0076; 04C0121; 04C0142;
Randomized Trial of Cladribine (CdA) with Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Collection of Human Samples to Study Hairy Cell and Other Leukemias and to Develop Recombinant Immunotoxins for Cancer Treatment
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
A Phase II, Open-label Study in Patients with BRAF V600E-Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib
Hematologic Malignancy Biology Study
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies#xD;
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies
Characterization of High-Risk Breast Duct Epithelium by Cytology, Breast Duct Endoscopy, and cDNA Gene Expression Profile
Proteomic-based Profiling of Lymphomas: Chromatin proteomics; composition and modification of histone and non-histone chromosomal proteins
Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome
Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells
Rapamycin-Resistant T Cell Therapy of Multiple Myeloma: Relapse Prevention and Relapse Therapy
Mobilization and Collection of Autologous Hematopoietic Progenitor Cell (HPC) for Transplantation (AHCT) for Plasma Cell Myeloma(PCM)
Expression of the Genome in Lymphoid Malignancies
The Acquisition of Blood and Skin Samples from Patient Volunteers to Support Research Activities on Dermatologic and Other Diseases
Evaluation and Treatment of Subjects with Dermatologic Diseases
Pharmacological Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Retrospective Analysis of Drug Disposition and Response-Related Genotypes in Cancer Patients and Correlation with Pharmacokinetics and Pharmacodynamics Data
Collection of Blood from Patients with Prostate Cancer
Collection of Tissue Blocks or Slides from Patients with Cancer
Collection of Blood from Patients with Cancer for Analysis of Genetic Differences in Drug Disposition
Long-Term Retention of Prospectively Obtained Biospecimens
Collection of Pharmacokinetic Samples from Patients with Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
Biospecimen Acquisition from Human Subjects
An Open Label Pilot Study to Evaluate the Safety and Tolerability of PANVAC(TM)-V (Vaccinia) and PANVAC (TM)-F (Fowlpox) in Combination with Sargramostim in Adults with Metastatic Carcinoma
Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or other immunotherapeutic agents
A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC[TM]-V (vaccinia) and PANVAC[TM]-F (fowlpox) in Adults with Metastatic Breast Cancer
First In-Human Phase I Trial of NHS-IL12 in Patients with Metastatic Solid Tumors
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men with Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (yeast) Genetically Modified to Express Brachyury Protein in Adults with Solid Tumors
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of avelumab (MSB0010718C), a monoclonal anti-PD-L1 antibody, in subjects with metastatic or locally advanced
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer or Normal Volunteers
Phase II Trial of Depsipeptide (NSC 630176) in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-cell Lymphoma
A Pilot Study of Tc-94m Sestamibi PET MDR Imaging
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
A Phase 1, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies
A Phase I Study of Belinostat in Combination with Cisplatin and Etoposide in Adults with a Focus on Small Cell Lung Cancer and other Cancers of Neuroendocrine Origin
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination with Trastuzumab in Breast Cancer Subjects with Brain Metastases
The Birt Hogg Dube' Syndrome: Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer
A Phase 2 Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Von Hippel Lindau Disease and Renal Tumors
A Phase II Study of ZD6474 (Vandetanib) in Patients with Von Hippel Lindau Disease and Renal Tumors
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant Diseases
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area
A Collaborative Case-Control Study of Genetic Associations, Biomarker Discovery and Risk Factors for Liver Cancer in Thailand
Multi-institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults#xD;
Autologous and Related Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Donor Program (NMDP)
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Study of the Biology and Natural History of Disease Outcomes in Patients Treated with Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies
Multi-institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution following Allogeneic Bone Marrow Transplantation in Post-pubertal Children and Adults with Molecular Imaging Evaluation
A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses with Administration of Glyco-recombinant Human IL-7 in Older Subjects Following Chemotherapy
Targeted Therapy of Bronchiolitis Obliterans Syndrome (BOS)
Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
Combination Antibody Therapy with Apolizumab [1D10] and Rituximab [CD20] in Relapsed Lymphoma and CLL
Phase 2 Trial of Alemtuzumab and Dose-Adjusted EPOCH In Chemotherapy Naive Aggressive T and NK-Cell Lymphomas
Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas
Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance versus Observation in Untreated Mantle Cell Lymphoma with Microarray Profiling and Proteomics
Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated de Novo Diffuse Large B-Cell Lymphomas
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Lymphoid Malignancies
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in T and NK-cell Lymphomas
Phase II trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in relapsed or refractory Diffuse Large B-Cell and Hodgkin Lymphomas
A RANDOMIZED PHASE II STUDY OF RITUXIMAB WITH ABVD VERSUS STANDARD ABVD FOR SUBJECTS WITH ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA WITH POOR RISK FEATURES (IPS SCORE gt; 2)
A Phase 2 Study of AZD6244 in Multiple Myeloma
Phase 1 Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Refractory de novo Diffuse Large B-cell Lymphoma
Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-cell and Peripheral T-cell Non-Hodgkin Lymphoma
A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly
A Multicenter Study of Ibrutinib and Lenalidomide in Combination with DA-EPOCH-R in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children with Previously Untreated Patients with Aggressive Non-Hodgkinamp;#39;s Lymphoma
Treatment and Natural History Study of Lymphomatoid Granulomatosis
EPOCH Chemotherapy Plus Rituximab for Previously Treated Patients with AIDS-Associated Lymphoma
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
Phase 2 Study of the C-Met RTK Inhibitor Foretinib (formerly GSK 1363089) in Subjects with Papillary Renal Cell Carcinoma (PRC).
A Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
A pilot study of F-18 paclitaxel (FPAC) PET for evaluating drug delivery to solid tumors
A pilot study of F-18 sodium fluoride PET/CT for metastatic burden quantification in prostate cancer
Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine
Acceptance and Commitment Therapy for Adolescents and Adults with Neurofibromatosis Type 1 and Chronic Pain: A Pilot Study
Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Young Adults with Chronic Illness and Their Parents
Effects of an Internet Support Group for Parents of a Child with Neurofibromatosis Type 1
Acceptance and Commitment Training for Adolescents and Adults with Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain: A Phase III Clinical Trial
Analysis of Stored Data Collected from Individuals Administered Neurobehavioral Assessments on IRB-approved Protocols
A Randomized Controlled Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated with Cranial Radiation for Brain Tumors
The Impact of Ras/MAPK Signaling Pathway-targeted Therapies on Neurocognitive Functioning in Individuals with NF1
An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin
Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies
A Phase II Protocol for Subjects with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radio-sensitizing Chemotherapy following a Thorough Transurethral Surgical Re-Staging
A Phase I Study of Image Guided Dose Escalation with Intensity Modulated Radiation Therapy (IMRT) to Histologically Confirmed Regions of Prostate Cancer
A Pilot Study of Image Guided Prostate and Pelvic Nodal Irradiation with Intensity Modulated Radiation Therapy (IMRT) in Prostate Cancer
A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch#xD; #xD;
Evaluation of Late Effects and Natural History of Disease in Patients Treated with Radiotherapy
Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols
Collection of Peripheral Blood and/or Urine from Patients Undergoing Radiation Therapy
A Phase II Study of MR-Guided High Dose Rate Brachytherapy Boosts for Prostate Cancer
Amifostine as a Rectal Protector During External Beam Radiotherapy for Prostate Cancer: A Phase II Study
Trans-Rectal Placement of Prostatic Fiducial Markers Under MR-Guidance in Patients Receiving External Beam Radiotherapy for Prostate Cancer: A Pilot Study
The Natural History of Childhood Malignancies Treated with Radiation Therapy
A Prospective Histopathologic Study of Dynamic Contrast Enhanced MRI for Prostate Cancer Delineation and Characterization with the APT-MRI System
Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence
A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination with Temodar and Radiation Therapy in Patients with High Grade Gliomas: A Multi-Institutional Trial
A Pilot Study to Evaluate Neuropsychological Outcome Measures and their Relationship with Prognosis in Patients Receiving Radiation Therapy for Brain Metastases
The Treatment of Stage I and II Carcinoma of the Breast with Mastectomy and Axillary Dissection vs. Excisional Biopsy Axillary Dissection, and Definitive Irradiation
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for Patients with GATA2 Mutations
Related and Unrelated Donor Hematopoietic Stem Cell Transplant for DOCK8 Deficiency
Apheresis and CD34+ Selection of Mobilized Peripheral Blood CD34+ Cells from Patients with DOCK8 Deficiency, LAD-1, and GATA2 Deficiency#xD;
Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC syndrome
Natural History of Plexiform Neurofibromas in Neurofibromatosis Type I
Phase I Trial and Pharmacokinetic Study of Tariquidar (XR9576), a P-Glycoprotein Inhibitor, in Combination with Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients with Refractory Solid Tumors Including Brain Tumors
Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in Children with Refractory Solid Tumors or Refractory Leukemias
Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents with Hereditary Medullary Thyroid Carcinoma
Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1
A Phase II Trial of Peginterferon alfa-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas
Phase 2 Study of Bevacizumab in Children and Adults with Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma
A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; Hydrogen Sulfate in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults with Relapsed / Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Phase I/II Trial of Mithramycin in Children and Adults with Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWS-FLI1 Fusion Transcript (Phase II)
SARC016: Phase 2 Study of the mTOR Inhibitor Everolimus in Combination with Bevacizumab in Patients with Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Longitudinal Assessment and Natural History Study of Children and Adults with MEN2A or MEN2B with or without Medullary Thyroid Carcinoma
Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients with Relapsed or Refractory Solid Tumors
A Phase I Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Phase II Trial of Vandetanib (ZD6474, Caprelsa(R)) in Children and Adults with Wild-Type Gastrointestinal Stromal Tumors
A Phase I/II Trial of Ganetespib in Combination with the mTOR Inhibitor Sirolimus for Patients with Recurrent or Refractory Sarcomas including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis
A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects with Neurofibromatosis Type 1 in Children and Adults
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults with NF1- Associated Morbid Plexiform Neurofibromas
A Feasibility Trial using Molecular-Guided Therapy for the Treatment of Patients with Refractory or Recurrent Neuroblastoma
A Phase II Study of Pegylated Interferon Alfa-2b (Peg-Intron) in Children with Diffuse Pontine Gliomas
A Comparative Study of Pediatric CNS Tumor Activity as Assessed by 18F-FDG PET Imaging and Proton Magnetic Resonance Spectroscopic Imaging (1H-MRSI)
A Phase II Trial of Tamoxifen and Bortezomib in Patients with Recurrent High-Grade Gliomas
An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients with Central Nervous System Tumors
A PHASE I TRIAL OF ENZASTAURIN (LY317615) IN COMBINATION WITH CARBOPLATIN IN ADULTS WITH RECURRENT GLIOMAS
A Phase II Trial of Enzastaurin (LY317615) in Combination with Bevacizumab in Adults with Recurrent Malignant Gliomas
A PHASE 2 TRIAL OF TANDUTINIB IN COMBINATION WITH BEVACIZUMAB FOR PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination with Carboplatin versus Carboplatin Alone Followed by Vandetanib Alone in Adults with Recurrent High-Grade Gliomas
A Phase I Trial of Lenalidomide and Radiotherapy in Children with Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas
PHASE I TRIAL OF AZD8055, AN ORAL MTOR KINASE INHIBITOR, FOR ADULTS WITH RECURRENT GLIOMAS
A Phase 1 and Phase II and Retreatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
A RANDOMIZED PHASE I/II STUDY OF ABT-888 IN COMBINATION WITH TEMOZOLOMIDE IN RECURRENT (TEMOZOLOMIDE RESISTANT) GLIOBLASTOMA
PBTC-033 A Phase I/II Study of ABT-888, an Oral Poly (ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas (DIPG)
A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients with Primary and Metastatic Brain Tumors
1H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients Who Receive Neurotoxic Therapy
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion with or without Concurrent Celecoxib in Subjects with Pulmonary and Pleural Malignancies
Prospective Evaluation of Genetic and Epigenetic Alterations in Patients with Thoracic Malignancies
Allogeneic Tumor Cell Vaccine with Metronomic Oral Cyclophosphamide and Celecoxib as Adjuvant Therapy for Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas
Adjuvant Allogeneic Tumor Cell Vaccine with Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum
Epigenetically-Modified Autologous Tumor Cell Vaccines and ISCOMATRIX(TM) Adjuvant with Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to
Phase I/ II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax) in the Therapy of Tac-Expressing Adult T-Cell Leukemia
A Phase I Investigation of IL-12/Pulse IL-2 in Adults with Advanced Solid Tumors
Phase II Study of the Efficacy and Toxicity of CAMPATH-1H in the Therapy of Adult T-Cell Leukemia
Phase I Trial of Medi-507 in CD2-Positive Lymphoproliferative Disease
A Phase I Open-Label Single-Dose Study of Humanized MIK-BETA-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R{beta} Subunit (CD122) in T Cell Large Granular Lymphocytic Leukemia
A Phase II Study of the Efficacy and Toxicity of ONTAK (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
A Phase I Study of Intravenous Recombinant Human IL-15(rhIL-15) in Adults with Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer
A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer
Phase I Study of the Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward IL-2/IL-15R beta (CD122) that Blocks IL-15 Action in Patients with Refractory Celiac Disease
A Phase I/II Study of Tac-Expressing Malignancies (Other than ATL) with Yttrium-90 (90Y)-Radiolabeled Humanized Anti-Tac and Calcium-DTPA
Collection of Blood, Bone Marrow and Tissue samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection
Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophelia Cohort (HGDS-3)
Discovery of Genetic Variants Contributing to the Incidence or Course of CMV Disease in AIDS Patients
BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects
Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols
Blood and Tissue Analysis in Surgery Branch NCI from Stored Samples
Phase II Study of Metastatic Cancer that Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
An Assessment of the Safety and Feasibility of Administering T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients with B-Cell Lymphoma
Follow-up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes#xD;
A Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor-Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction with
A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma
A Phase I/II Study of the Safety and Feasibility of Administering T-Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients with Malignant Gliomas Expressing EGFRvIII#xD;
A Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-Mesothelin Gene Engineered Lymphocytes#xD;
A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma
A Phase II Study of Lymphodepletion followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers
A Phase II Study of Metastatic Cancer that Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY-ESO-1 Murine TCR-Gene Engineered Lymphocytes
A Phase II Study for Metastatic Melanoma Using High-Dose Chemotherapy Preparative Regimen Followed by Cell Transfer Therapy Using Tumor-Infiltrating Lymphocytes Plus IL-2 with the Administration of Pembrolizumab in the Retreatment Arm
A Phase I/II Study of the Treatment of Metastatic Cancer that Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin
Phase II Study of CD62L+-derived T lymphocytes transduced with a T Cell Receptor Recognizing the NY-ESO-1 Antigen and Aldesleukin Following Lymphodepletion in Patients with NY-ESO-1 Expressing Melanoma
A Phase II Study of Cell Transfer Therapy for Metastatic Melanoma Using 41BB Selected Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen
Phase I/II Study of the Treatment of Metastatic Cancer that Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3 HLA-A*01 Restricted TCR-Gene Engineered Lymphocytes and Aldesleukin
A Phase I Trial for the Evaluation of the In Vivo Persistence of Adoptively-transferred Tumor-Infiltrating Lymphocytes Cultured with a Pharmacologic Inhibitor of AKT in Patients with Metastatic Melanoma
Evaluation for NCI Surgery Branch Clinical Research Protocols
Biomarker Analysis of Lymphoma and Lymphoproliferative Diseases
DNA Methylation in Gray Zone Lymphoma compared to Hodgkin Lymphoma, Primary Mediastinal Large Cell Lymphoma and Diffuse Large B-Cell Lymphoma
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with HIV Infection, KSHV Infection, Viral-related Pre-malignant Lesions, and/or Cancer
Protocol to Assess Vascularity in Kaposi's Sarcoma Lesions Utilizing Non-invasive Tumor Imaging
Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease with Laboratory and Clinical Correlates of Disease Activity
AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate with Rituximab, Leucovorin Rescue and Highly Active Antiretroviral Therapy
Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in Patients with Kaposiamp;#39;s Sarcoma
Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab Followed by Bevacizumab Monotherapy in Adults with Advanced Kaposiamp;#39;s Sarcoma
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) Incorporating Pilot Evaluation of KSHV Targeted Therapies
A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV
Cancer Risk in Xeroderma Pigmentosum Heterozygotes
Examination of Clinical and Laboratory Abnormalities in Patients with Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
A Phase 0 Trial of [111]Indium CHX-A DTPA Trastuzumab Imaging in Cancer
Pilot Study of Educational Interventions in Pediatric Hematopoietic Stem Cell Donors to Increase Knowledge of Donation and Transplantation Procedures
Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer
Understanding the Perceived Influence of Childhood Cancer on the Parents' Marital/partner Relationship: A Descriptive Study
An Exploratory Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults with Cancer and Other Life Threatening Illnesses
A Group Wide Biology and Banking Study for Phase II Studies of R1507
Phase 1 Study of a Combination of the PARP inhibitor, Niraparib and/or Temozolomide in Patients with Previously Treated, Incurable Ewing's Sarcoma
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults with Tumors with 1-3+ HER2/neu Expression
A Randomized, Placebo-Controlled Phase II Study of Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men with Stage D0 Prostate Cancer
A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccine in Previously Vaccinated Men on NCI 09-C-0139.
Combination therapy tested in clinical trial for metastatic genitourinary cancers
Peter Choyke and Louis Staudt elected to the National Academy of Medicine
Phase 1 CAR T-cell therapy leads to years-long remissions in relapsed B-cell lymphoma patients
Clinical trial tests immunotherapy combination for advanced HPV-associated cancers
Clinical trial tests vaccine for late-stage HPV-linked tumors
Lymphoma therapy drug tested as early treatment for chronic graft-versus-host disease
Ira Pastan receives 2020 Paul A. Volcker Career Achievement award
Ruth Nussinov and Kandice Tanner named American Physical Society Fellows
Jordan Meier receives the 2021 Eli Lilly Award in Biological Chemistry
Sue Wickner receives the 2021 American Society for Microbiology Award for Basic Research
Breast Cancer Research
Combination therapy for solid tumors and small-cell cancers studied in new clinical trial
Clinical trial studies combination immunotherapy for colorectal cancer
Registration Open: Enhancers, Gene Regulation and Genome Organization
ARS deadline
Selumetinib offers hope as first FDA-approved treatment for neurofibromatosis 1 (NF1)
Clinical trial evaluates a combination therapy for metastatic clear cell renal carcinoma
Nominate your postdoc for the 2021 Outstanding Postdoctoral Fellow Award
WSA listening session
In Memoriam: Larry K. Keefer, Ph.D.
Clinical trial evaluates immunotherapy for head and neck cancer caused by HPV
Trial opens to evaluate a potential anti-metastasis compound
Clinical trial will evaluate chemotherapy-sparing approach to treating Kaposi sarcoma
Undergraduate research at NCI sparks curiosity and new connections
Innovative imaging tools reveal how neutrophils fight inflammation in mice
CCR Clinical All Hands Meeting - September 14
FDA grants rare pediatric disease designation for experimental immunotherapy for acute lymphoblastic leukemia
In mice, new therapeutic strategy enhances the effects of immunotherapy in high ASS1-expressing cancers
Our leukemia and lymphoma research
Experimental compound blocks SARS-CoV-2’s ability to infect and kill cells in the lab
Clinical trial studies three immunotherapies given before surgery in newly diagnosed head and neck cancers not caused by HPV
Epigenetic marker contributes to PARP inhibitor resistance
New synthetic compounds alter RNA expression in bacteria
Supervisors mandatory training
Annual mandatory training requirement for supervisors
Outdoor campus barbecues
Food Truck Schedule
Need emotional support during the COVID-19 pandemic?
A Conversation with Adam Sowalsky, Ph.D.
Clinical trial evaluates radiopharmaceutical as therapy for biochemically recurrent prostate cancer
ARS reminder for CCR central
Welcome back Group B
Welcome Group B
Immunotherapy clinical trial tests therapy for metastatic solid tumors
Two patient’s stomachs kept “alive” after removal in novel study to understand stomach cancer
Joe Chinquee volunteers with Navajo Nation during COVID-19 pandemic
In Memoriam: Flossie Wong-Staal, Ph.D.
Lieutenant and Research Nurse Matt Lindsley shares his experiences and public service role
Mary Kearney discusses coronavirus with National Geographic
Clinical trial tests combination therapy for glioblastoma multiforme
In Memoriam: Gilbert Howlett Smith, Ph.D.
Apply now for the Pamela Anne Cafritz Renal Cell Carcinoma Award
NIH security management refresher training due July 10
Sarcoma Awareness Month
Trial shows aggressive cancer treatment is appropriate for people with HIV-associated primary central nervous system lymphoma
Study finds drug beneficial for shrinking mesothelioma tumors
Clinical trial studies combination therapy for certain mature T-cell cancers that have not responded to treatment
Clinical trial tests targeted radioactive agent as therapy for metastatic prostate cancer
A Conversation with Christina Annunziata, M.D., Ph.D.
Clinical trial studies immunotherapy for head and neck cancer caused by HPV
New chemical sequencing reaction helps unravel the role of an ancient RNA modification
Clinical trial studies CAR T-cell therapy for relapsed/refractory acute myeloid leukemia
Welcome back CCR Group A!
Stop the spread of COVID-19
Kindly do not visit today...
For everyone's health and safety
New clinical trial evaluates chemotherapy delivery for stomach cancer
CCR presentations at AACR 2020 - Session II
CCR scientists develop new blood test that may improve liver cancer screening
We’ll be back soon!
Do the CCR digital signs look "odd"?
In Memoriam: Isaiah Fidler, D.V.M, Ph.D.
A Conversation with Bríd Ryan, Ph.D., M.P.H.
Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma
FDA approves pomalidomide for AIDS-related Kaposi sarcoma
In Memoriam: Stephen Oroszlan, Ph.D.
Eytan Ruppin quoted in New York Times story on treating COVID-19
Ira Pastan selected as a 2020 Sammies finalist
John Schiller elected to the National Academy of Sciences
NCI initiative aims to boost CAR T-cell therapy clinical trials
Andrea Apolo receives Arthur S. Flemming Award
Dr. William Dahut discusses coronavirus and cancer patients on Frankly Speaking about Cancer podcast
The discovery of selumetinib for children with NF1
FDA approves first therapy for children with neurofibromatosis type 1
New genetic analysis will help researchers understand how diffuse large B-cell lymphoma subtypes respond to experimental therapies
Mouse models and patient data suggest potential biomarker for immunotherapy response in melanoma
In Memoriam: Nancy Colburn, Ph.D.
CCR Guidance for Staff on Coronavirus (2)
Ask CCR Email
CCR researchers show selumetinib shrinks tumors in children with NF1
New Milestones publication now available
New study overturns conventional understanding of how HIV infection occurs
Potent new LDHI inhibitor disrupts tumor growth in mice
frank lin irp
irp blog john fenimore aarti kolluri
gift of gerberts feathers
Woo Kyung Lee award ATA
hinrichs rosenberg flc
Housing resources for out-of-town students
Revised NIH manuscript clearance form
CCR job openings - March
Samantha Seinfeld NBC 4
Researchers identify protein essential for assembling cells’ energy-producing machine
New tool catalogs thousands of previously unknown viruses
Brudno Kochenderfer blurb
James Dunleavey, Ph.D. Department of Defense Peer-Reviewed Cancer Research Program (PRCRP) Horizon Award
Dahut Georgetown Award
CCR Women Scientist Advisors (WSAs) speed-networking event
POB congressional visit
NIH policy on Personal Relationships in the Workplace
PubMed Central compliance
Genomic Data Commons (GDC) Monthly Support Webinar: GDC’s Data Model
New NIH Hematology-Oncology Fellowship website
Nominate your colleagues for the SS/SC Outstanding Mentor Award
Communicating within CCR
CCR researchers show testing with combined biopsy method improves prostate cancer diagnosis
Christian Hinrichs and Steve Rosenberg receive Federal Laboratory Consortium award
A new set of genes linked to metastasis in melanoma
Clinical trial studies combination therapy for mesothelin-expressing solid tumors
Irinotecan shrinks DNA-repair-deficient breast cancers in patient-derived mouse models
Udo Rudloff and team develop potential new type of immunotherapy
NIH Property Portal Implementation - Building 37
NIH Wednesday Afternoon Lecture Series
New study overturns conventional understanding of how HIV infection occurs
BTEP Variant Analysis Software Demonstration
Jennifer Brudno and James Kochenderfer discuss reduced side effects of remodeled CAR T-cell therapy
Potent new LDHI inhibitor disrupts tumor growth in mice
Learn to Analyze Your Gene Expression Data with Qlucore Omics Explorer
Researchers identify protein essential for assembling cells’ energy-producing machine
Kochenderfer Top 10 clinical research
CCR FREDERICK FACULTY SEMINAR SERIES - February 26
CCR Grand Rounds - February 21
CCR Grand Rounds - February 28
CCR job openings
Follow the Laboratory of Pathology on Twitter
Protein affecting cell division hints at a way to overcome drug resistance
Genomic profiles of lung cancer differ based on ancestry
Lou Staudt podcast
Erin Davis TTI
CCR FREDERICK FACULTY SEMINAR SERIES - February 19
CCR FREDERICK FACULTY SEMINAR SERIES - February 12
myNCI Headshot Photo Session
Genomic Data Commons (GDC) webinar: Clinical Data Analysis in the GDC Data Portal
Updated CCR Research page
Immunology and Immunotherapy
Nominations open for new SS/SC Merit Awards
Mandatory requirement: Verify your NIH assigned property
Congratulations to the inaugural NCI Transition to Industry (T2I) fellows
New technology elucidates how metabolites interact with proteins to drive cancer
Side effects of CAR T-cell therapy are dramatically reduced with new receptor
CTA VB
Heather Chalfin GUMDROP
DCDP SIA
Did you know every CCR branch has its own web content managers?
Employee Assistance Program (EAP) available to help
10th Annual NCI-UMD Partnership for Integrative Cancer Research Symposium
Young Professionals & Collegiate Symposium “Cultivating Talent for Tomorrow”
myNCI Headshot Photo Shoot - Frederick Campus
Meet with your Technology Transfer Manager (TTM) before AACR and ASCO
NIH Office of AIDS Research (OAR) accepting proposals for Innovation Funds
Congratulations to the inaugural CCR Outstanding Ph.D. Student Awardees
Join the CCR FYI committee
New tool catalogs thousands of previously unknown viruses
James N. Kochenderfer receives Top Ten Clinical Research Achievement Award
DNA Repair Interest Group Seminar - February 18
BTEP Distinguished Speaker Seminar Series - February 6
CCR Grand Rounds - February 7
Online Registration Deadline Approaching for the 20th Annual CCR-FYI Colloquium
Clinical trial tests combination immunotherapy for genitourinary tumors
T-cell stimulation could be used to target cancers with common TP53 gene mutations
New technology elucidates how metabolites interact with proteins to drive cancer
Special LCBG Seminar - February 6, 2020
Side effects of CAR T-cell therapy are dramatically reduced with new receptor
Now recruiting: Combination therapy clinical trial for small-cell lung or small-cell extrapulmonary cancers
Clinical trial evaluates T-cell therapy for advanced mesothelin-expressing cancers
Unlocking the key to HIV persistence
New findings hint at therapies for African Americans with lung cancer
CCR Frederick Faculty Seminar Series - January 29
New job toolkit to help with hiring in your lab
Shah Takeda Lasker
Ron Gress Forbes
Congratulations to the CCR staff who were recognized at the Third Annual Clinical Center CEO Awards program.
Genomic Data Commons (GDC) webinar: Data sharing
CCR job openings
February 11th is International Day of Women and Girls in Science
Genomic profiles of lung cancer differ based on ancestry
Clinical trial investigates IV administration of vaccine for advanced solid tumors
Julie Jones toy donation
Differences between anti-viral and anti-tumor T-cell responses could impact immunotherapy
Binding preferences of Ras and Raf yield clues for developing targeted cancer therapies
NCI Directors Awards
Genoveffa Franchini, M.D. Doctor Honoris Causa
SS/SC RA
Winter REiNs successes
We want to feature you and your team!
CCR Frederick Faculty Seminar Series - January 15
CCR Grand Rounds - January 24
Over 44,000 AACR Project GENIE cases available in the GDC
Interested in a career transition to the commercial side of technology development?
New CCR Women Scientist Advisors elected
FDA grants orphan drug designation to zotiraciclib for the treatment of glioma
FDA grants orphan drug designation to zotiraciclib for the treatment of glioma
Protein affecting cell division hints at a way to overcome drug resistance
Biological Discovery and Design using Machine Learning
DNA Repair Interest Group Seminar - January 21
Jay Berzofsky and Hoyoung Maeng discuss new vaccine to help men with prostate cancer
Former Pediatric Oncology Branch patient donates toys to NIH Pediatric Clinic
Ben Langmead (JHU), Marshaling Public Data for Lean and Powerful Splicing Studies
Clinical Center Pharmacy Relocated
Binding preferences of Ras and Raf yield clues for developing targeted cancer therapies
Histone deacetylase inhibitors block cancer-driving gene networks by obstructing DNA folding
Differences between anti-viral and anti-tumor T-cell responses could impact immunotherapy
Differences between anti-viral and anti-tumor T-cell responses could impact immunotherapy
NIH Wednesday Afternoon Lecture Series
New findings hint at therapies for African Americans with lung cancer
Christopher Buck recently featured in Nature Index article
Ronald Gress discusses therapeutic potential of supercentinarian immune cells
Martha Zeiger elected President of the American Thyroid Association
Newest Lasker Scholars Nirali Shah and David Takeda featured in Intramural Research Program blog
Travis Carpenter NASCAR
Alexander Wlodawer the poster
Chris Kanakry COSTEM interview
Xiyuan Zhang, M.S., Ph.D. DOD award
Want to post an announcement on CCR's digital screens?
CCR FREDERICK FACULTY SEMINAR SERIES - December 18
Physician-Scientist Early Investigator Program website refresh
Updated content on CCR Central
CCR job openings
Follow the RNA Biology Laboratory (RNABL) on Twitter
Tim Greten IRP BLOG
Martha Zeiger ATA award and president
Brigitte Widemann NICHD
Takanobu Tagawa poster winner
POB research ethics discussion
Conquer journal title pages in seconds
December safety message
CCR Grand Rounds - December 13
New video: Discovering new far-red fluorescent probes
Clinical Trial Conversation
Commercial partnership opportunity: Cell growth tools
Submit comments on draft NIH data management and sharing policy
NIH Independent Research Scholar (IRS) Program recruiting
Chris Buck nature index article
Kochenderfer ASCI
John Beutler AAAS
Scott Durum Affordable Rock'n'Roll Act
Gingerbread houses 2019
CCR FREDERICK FACULTY SEMINAR SERIES - December 11
20th Annual CCR FYI Colloquium
Genomic Data Commons (GDC) support webinar: The GDC Application Programming Interface
POSTPONED: RNA Imaging and Intracellular Dynamics Workshop
POSTPONED: 3rd NCI Symposium on Cancer Health Disparities
Upgraded look for ccr.cancer.gov
2020 Summer Internship Program application now open
iCURE now accepting applications
Jonathan Hernandez named one of Washington, D.C.’s best doctors
Jonathan Hernandez selected as top doctor
DNA Repair Interest Group Seminar
Unlocking the key to HIV persistence
Clinical trial evaluates T-cell therapy for advanced mesothelin-expressing cancers
Abstract Submission Open for the 20th Annual CCR-FYI Colloquium
Computational analysis leads to potential new drug combination for pancreatic cancer
Clinical trial will test radiotracer imaging for high-risk localized prostate cancer
New video: Discovering new far-red fluorescent probes
Clinical trial tests combination therapy for relapsed hairy cell leukemia
Samantha Seinfeld BCSM
Chen Zhao ACI
Reddit AMA
U01 grants
Congratulations to the 2020 NCI Director’s Innovation Award recipients
CCR Careers Research Faculty
Hernandez Clinical Research Team
NCI CCR Medullary Thyroid Carcinoma Clinic
Tim Greten OncLive
Nirali Shah CCH Research Grant
David Takeda TTI
Steve Rosenberg Friends of Cancer Research Cancer Leadership Award
Jordan Meier awarded tenure
Need to post a job vacancy or update the team members on your web profile?
CCR Frederick Faculty Seminar Series - November 20
Updated content on CCR Central
January is Mentor Appreciation Month
Need to log on to CCR Central?
LeBlanc Everyday Health
Mackey O-6
kent hunter EDI award
Remi Adelaiye-Ogala Mike Beshiri 2019 PCF
CCR AHCJ tour
November safety message
Complete the mandatory research ethics case discussion
CCR Grand Rounds - Dec 6
CCR Grand Rounds - Nov 22
Mechanobiology Across Length Scales
Furlough or inclement weather? Know your status with the OPM Alert Mobile App
Congratulations to the 2019 CCR Excellence in Postdoctoral Research Transition Award winners:
Eighth Annual David Derse Memorial Lecture and Award
BTEP Distinguished Speaker Seminar Series
2020 Outstanding PostGraduate Fellow Award
Molecular HCC Rise Prediction and Chemoprevention
DNA Repair Interest Group Seminar Nov 19
Pancreatic Cancer Research
Lung Cancer Research
Clinical Center Pharmacy
Elaine Jaffe named an NIH Distinguished Investigator
Clinical trial will test new treatment to improve survival rates for patients with operable gastrointestinal tumors
CCR Grand Rounds - November 1
Clinical trial studies antibiotic therapy for fibrolamellar hepatocellular carcinoma, a rare liver cancer
CBIIT Image Analysis Seminar Series: From Images to Numbers: Analysis of Highly Multiplex Immunofluorescence Data with Indica HALO™
James Kochenderfer receives 2019 FNIH Trailblazer Prize for Clinician-Scientists
Metastatic breast cancer survivor shares her clinical trial story
Stanley Lipkowitz and Alexandra Zimmer answer breast cancer “Redditor” questions
Kenneth Aldape discusses importance of precise diagnosis in brain and spine tumors
Andre Nussenzweig elected to the National Academy of Medicine
Test with image
Clinical trial studies combination therapy for B-cell lymphoma that has spread to the central nervous system
Clinical trial tests chemotherapy dose for graft-versus-host disease after bone marrow transplant
Tim Greten discusses liver cancer with OncLive
Amy LeBlanc discusses how dogs are helping cure childhood cancers
Euna Yoo TTI
CCR Postbac event
Don’t forget to follow PubMed Central requirements
CCR Frederick Faculty Seminar Series - October 23
CCR Frederick Faculty Seminar Series - October 16
Lowy Schiller NYT
Marston Linehan the Federalist podcast
Larry Samelson Coley Award
Meera Murgai TTI
Vanja Lazarevic, Ph.D. Senior investigator
Elaine Jaffe the Pathologist
Ravi Madan Congressional Mens Health Caucus
POB Fb live
Did you know?
New NIH data publication platform available to CCR researchers
October safety message
Learn more about the NCI Transition to Industry (T2I) Postdoctoral Fellowship
Save the date: CCR-FYI Colloquium
The Human Genome: How much are we missing?
Clinical Proteomic Tumor Analysis Consortium
CRISPR libraries now available
Diversity of liver cancer cells can impede tumors’ response to immunotherapy
New requirement for minimum monthly network use
Dom Camp Fantastic
Michael Gottesman Ira Pastan, M.D.
Sridhar Hannenhalli Senior Investigator
Freed Distinguished Career award
House Appropriations committee visit
iCURE welcome ceremony
Christian Hinrichs James Kochenderfer Senate Cancer Coalition
Submit applications for the Staff Scientist and Staff Clinician Research Award
Diversity Career Development Program now accepting applications
Deadline approaching for the Sallie Rosen Kaplan (SRK) Postdoctoral Fellowship for women scientists
Gottfried Wilhelm Leibniz Prize, Lecture and Reception
Single Cell RNA-Seq Workshop
NCI Core Facilities Open House
Monthly Genomic Data Commons support webinars
Take the mandatory anti-harassment training by November 15
IN STEP Cloud Resources Funding Opportunity
Nominate your postdoc for the 2020 Outstanding Postdoctoral Fellow Award
Steve Rosenberg receives Friends of Cancer Research Cancer Leadership Award
DNA Repair Interest Group Seminar
Brajendra Tripathi featured in Journal of Cell Biology
Lawrence Samelson receives Cancer Research Institute Coley Award
Marston Linehan discusses kidney cancer breakthroughs with the Federal News Network podcast
The New York Times highlights the importance of physician-scientists
Advanced imaging technology reveals pulsed hormone release regulates gene transcription
The Center for Cancer Research celebrates National Postdoc Appreciation Week
Karlyne Reilly discusses childhood cancer on BioMedCentral
Tumor composition of melanoma indicates potential responses to immunotherapy
Neurofibromatosis type 1 patient attends Camp Fantastic for the first time
Michael Gottesman and Ira Pastan featured in NIH Intramural Research Program podcast
Inflammation, Immunological Memory and Aging Symposium
Lori Wiener selected as NYU Alumni Changemaker
FDA grants breakthrough therapy designation for new CAR T-cell therapy for B-cell acute lymphoblastic leukemia
Test content
Camp Fantastic live tweets
Qianfei Zhang 2019 Marion U. Schwartz Memorial Research Fellowship
Martha Zeiger, M.D., has joined the Surgical Oncology Program.
Joshua Welsh, Ph.D 2019 Marylou Ingram Scholar by the International Society for the Advancement of Cytometry (ISAC).
CCR Frederick Faculty Seminar Series - September 25
CCR Grand Rounds - October 4
Eugene Valkov, Ph.D. Stadtman Tenure Track Investigator
Bill Telford, Ph.D International Society for the Advancement of Cytometry (ISAC) Distinguished Service Award
S. Cenk Sahinalp, Ph.D., Senior Investigator
We want to feature you and your team!
Review the NIH Guidelines for the Conduct of Research
CCR Frederick Faculty Seminar Series - September 11
Submit proposals to the NCI Antibody Engineering Program (AEP)
Nitin Roper, M.D., M.Sc Assistant Clinical Investigator
Martha Quezado Senior Research Physician
Laurie Krug, Ph.D. Stadtman Tenure Track Investigator
Access to proprietary agents available through Umbrella CRADAs
September safety message
Staff Scientist/Staff Clinician quad review information session
Upcoming BTEP training
Updated forms available for hESCs and iPSC use
Ken Kraemer Associate Press
Mary Kearney, Ph.D. Senior Scientist
Katie Hebron, Ph.D. Summer’s Way/Friends of TJ Young Investigators Grant
Myriem Boufraqech, Ph.D grant from the American Thyroid Association
Summer postbac day
Taiwan MOST visit
Clinical All Hands
Translational Research in Clinical Oncology (TRACO) course opens soon
Clinical Trial Conversation with Tim Greten
National Postdoc Appreciation Week - 2
National Postdoc Appreciation Week
Clinical Proteomic Tumor Analysis Consortium Scientific Symposium
Clinical trial evaluates dual drug therapy for untreated follicular lymphoma
Steve Rosenberg receives 2019 Edogawa NICHE Prize
CCR Grand Rounds - September 6
James Kochenderfer named finalist for 2019 FNIH Trailblazer Prize for Clinician-Scientists
NCI CCR Liver Cancer Program Speaker
Clinical Trial Conversation: Tim Greten describes primary liver cancer clinical trial
Bill Telford receives 2019 International Society for the Advancement of Cytometry Distinguished Service Award
Researchers develop a new imaging technique to measure cancer metabolism
DNA Repair Interest Group Seminar
The NIH Collaborative Research Exchange (CREx)
Jack Shern featured in LocalDVM news article
New clinical trial tests CAR T-cell therapy for multiple myeloma
Clinical trial tests combination therapy in untreated aggressive B-cell lymphomas
Tumor cells in transparent fish reveal physical and molecular factors that determine metastasis sites
Clinical Proteomic Tumor Analysis Consortium Scientific Symposium
FDA grants breakthrough therapy designation of new TIL therapy for advanced cervical cancer
Ken Kraemer featured in Associated Press
Mark your calendars for the 20th Annual CCR-FYI Colloquium
Ramya Ramaswami ACI
AAAS Award winner
Visit the OD staff directory
Housing resources for out-of-town fellows
Follow the Cancer Data Science Laboratory (CDSL) on Twitter
Ying Zhang IRP blog post
Amy LeBlanc WIRED article
Doug Lowy AACI Award
Peng Jiang Stadtman TTI
Cancer Survivor Caucus visit
NCI Navy 40th Anniversary
Obtain research funding through collaborations
August safety message
Therapeutic Interventions and Resistance Mechanisms
NIH Research Festival
Submit LOIs for CCR FLEX Program
Did you know? Publishing manuscripts
In patients with severe chronic lymphocytic leukemia, B cells get stuck in hyperactive mode
Amy LeBlanc featured in Wired
Landmark discovery: H2AX as a sensor of DNA damage
New mechanism for regulating differentiation discovered in human embryonic stem cells
Ying Zhang’s research featured in new NIH Intramural Research Program blog
Doug Lowy receives Distinguished Scientist Award from the Association of American Cancer Institutes
Gene-regulating microRNAs gain control over hundreds of new genes with common sequence modification
CCR scientists receive the Presidential Early Career Award for Scientists and Engineers
Hernandez Behind the Knife podcast
Changqing Xie ACI
schiller hpv congressional hearing
Schneekloth tenure
Tom Misteli Foreign Fellow
Karlyne Reilly The Hill’s Future of Healthcare Summit
Sign up for the new MyPART newsletter
Follow the Pediatric Oncology Branch (POB) on Twitter
Clinical Trial Conversation with Jonathan Hernandez
tim greten and naomi taylor CoEI
Heme onc fellowship graduation
Congratulations to the CCR PECASE recipients
Want to post an announcement on CCR's digital screens?
Reporting inventions to your Technology Transfer Manager (TTM)
CCR Central video tutorials now available
CCR Excellence in Postdoctoral Research Transition Award program accepting applications
Bilusic DCTA
Mari Yohe - HHS Regional Directors visit
Mina Bissell GR lecture
Did you know?
NIH Workplace Climate Survey interim results
NCI CCR Liver Cancer Program: Special Conference on Tumor Metabolism
CCR Staff Scientist/Staff Clinician Conversation with Director Tom Misteli, Ph.D.
Take the 2019 Information Security and Management Refresher Course
Read the new CCR Landmarks story
Clinical Trial Conversation: Jonathan Hernandez describes metastatic colorectal cancer clinical trial
Jonathan Hernandez discusses surgical oncology with Behind the Knife podcast
Sarcoma Awareness Month
Clinical trial tests immunotherapy combination to treat T-cell cancers
Clinical trial will test immunotherapy against precancerous vulvar lesions
Gastrointestinal tumors harbor T cells that recognize patients’ unique tumor antigens
Research shows long noncoding RNA influences expression of key HIV receptor
Pediatric Oncology Branch patient shares neurofibromatosis journey at NIH
BTEP Summer Sessions
Akt protein kinase pathway regulates key step in the initiation of cilia formation
Registration now open for Cancer and Inflammation: From Micro to Macro
CCR fellows receive Conquer Cancer Foundation of ASCO Young Investigator Awards
CCR RNA Biology Initiative Seminar Series
Bacterial compound targets cancer-promoting RNA
Xavier Patient story
Frontiers in Light Microscopy
Chromatin and Cell Fate Decisions in Development, Aging and Cancer
Pamela Anne Cafritz awardees
Conquer Cancer Foundation YIA winners
SS/SC retreat winners
Chen Zhao SITC
Pediatric Oncology Branch and other NCI staff host congressional staff
Frederick National Laboratory (Leidos) feedback tool
RNA Initiative Retreat
Cancer and Inflammation: From Micro to Macro
Prostate Cancer Multidisciplinary Clinic
Shah NIH distinguished scholar
Ji Luo tenured
NIH Clinical Center nurse receives NCI CCR Medical Oncology Service award
Pediatric Oncology Branch Research Round-Up
Animal care training for summer students
Identify your Technology Transfer Manager (TTM)
Genitourinary Malignancies Center of Excellence Seminar
NIH Safety Health and Wellness Day
Dan Larson, tenure
Figg honorary doctorate of science
Postbac Poster Day 2019
NRC Commissioner visits the NIH
Updating web content
Current job openings
NIH EDI Empowerment Series: Hustle Your Way to Career Success
Annual Camp Fantastic BBQ
June is Cancer Immunotherapy Month
Take the 2019 Federal Employee Viewpoint Survey by July 1
Nirali Shah and Lori Wiener participate in AtlanticLIVE summit
Udo Rudloff discusses germline mutations with Bloomberg podcast
Clinical trial tests new methods for blood stem cell transplant in lymphoma
June is Cancer Immunotherapy Awareness Month
Investigators test combination therapy for head and neck squamous cell carcinoma in new trial
DNA Repair Interest Group Seminar - June 18
Registration now open for Frontiers in Light Microscopy
Clinical trial tests a new drug therapy for recurrent ependymomas of the brain and spinal cord
Nataliya Buxbaum wins Magnetic Moments video competition
Clinical study follows men with specific genetic changes to determine their risk for developing prostate cancer
Special CCR Grand Rounds Lecture - 2019 AAAS Martin and Rose Wachtel Cancer Research Award and Lecture
Clinical trial to determine whether antibiotics can boost immune response in treating liver cancer
Julius Strauss discusses promising immunotherapy drug for patients with HPV-related cancers
Brid Ryan cohosts NCI Minority Health Month Facebook Live
Keys to Establishing your Mentor Network
Save the Date: Mentor - Mentee Mixer
CCR Frederick Faculty Seminar Series - June 12
CCR Frederick Faculty Seminar Series - June 5
Congratulations to the following staff scientists who received new professional designations:
Joseph Ziegelbauer, Ph.D awarded tenure at NIH and appointed to Senior Investigator
NCI Facebook Live: A Dialogue on Cancer Disparities, Prevention and Research
CCR Frederick Faculty Seminar Series - May 22
CCR Grand Rounds - June 21
Gabe Starrett, Ph.D selected to join the inaugural class of NIH Independent Research Scholars
Nirali Shah, M.D., MHSc appointed as an NIH Lasker Scholar Tenure Track Investigator
Dr. Stephen Katz Memorial
2019 Postbac Poster Day
We want to feature you and your team!
CCR Grand Rounds - June 14
CCR Grand Rounds - June 7
Women Leaders in Biotech and Pharma Seminar Series
Looking for commercialization partners?
Call for proposals: Bench-to-Bedside awards
Undergraduate Research Scholar Program fellow continues her pursuit of science
African Postdoctoral Training Initiative fellow looks forward to collaborating within NCI
Linehan selected as a SAMMIE finalist
Philipp Oberdoerffer, Ph.D. and Pedro Batista, Ph.D. DOD Grant
Amy LeBlanc, D.V.M. appointed as a Senior Scientist
15th Annual CCR and DCEG Staff Scientist and Staff Clinician Retreat
Administrative Professionals Day appreciation breakfast
Did you know every CCR branch has their own web content managers?
2nd NCI-Curie Institute Meeting
Pediatric Oncology Branch Research Roundup
Congressional Directed Medical Research Programs (CDMRP) webinar series
2018 HHS Departmental Awards
Freddy Escorcia Postbac Mentor of the Year
Renee Donahue Distinguished Alumni Award from Penn State
First NIH Myeloid Malignancy Scientific Interest Group
9th Annual Women Scientist Advisors (WSA) Scholars Symposium
May safety message
WSA Meet and Greet
NCI Staff "Town Hall"
Our Patients Make it Possible - Randy
Check out the NIH Bioinformatics calendar
FDA breakthrough designation for selumetinib
NCI CCR Liver Cancer Program Speaker
A patient’s 10-year journey to moxetumomab for hairy cell leukemia
Cyclophosphamide works in an unexpected way to curb graft-vs-host disease in mice
Marston Linehan receives 2019 Urology Care Foundation Distinguished Mentor award
DNA Repair Interest Group Seminar
iCURE helps a first-generation American reach her goal
Majority of patients with advanced multiple myeloma respond to CAR T-cell therapy targeting an anti-B-cell maturation antigen in a phase I trial
Heritable mutations may indicate responsiveness to platinum chemotherapy in malignant mesothelioma
NIH "Eagle Horizon" Personnel Accountability Drill May 6-10, 2019
Undergraduate Research Scholar Program fellow continues her pursuit of science
New clinical trial tests radiotracer for improved imaging of metastatic prostate cancer
Clinical trial tests a PARP inhibitor in urothelial cancer with DNA-repair defects
African Postdoctoral Training Initiative fellow looks forward to collaborating within NCI
CCR Grand Rounds - May 10
Envelope glycoprotein mutations allow HIV-1 to escape antiretroviral therapy in a lab-based study
MEK inhibitor selumetinib granted breakthrough designation by FDA to treat neurofibromatosis type 1 in pediatric patients
Elaine Jaffe receives the 2019 USCAP Board’s Distinguished Pathologist award
CCR Grand Rounds - May 3
Goff - Stephanie Goff
Restifo Science Paper
Did you just get a paper accepted?
Interested in collaborating with the industry or academia?
Need to post a job on the CCR Careers website?
CCR Frederick Faculty Seminar Series April 24
Masaki Terabe, Ph.D TTI
Louis Staudt AACR fellow
CCR Frederick Faculty Seminar Series April 17
CCR Frederick Faculty Seminar Series April 10
NCI Flow Cytometry Training Course
Parisa Malekzadeh, M.D. Harvey Baker Traveling Fellow award
Elaine Jaffe, M.D USCAP Board’s Distinguished Pathologist award
CCR Staff at AACR
NCI Graduate Student Recruiting Program (NCI-GSRP)
Symposium on Employee Support Services: "Who Do I Call?"
Congratulations to the 2019 CCR DoD Grant recipients
Gnotobiotics Facility available for NCI staff use
PI Retreat photo gallery
New video for first-time pediatric patients
Save the date
Women Leaders in Biotech and Pharmacy Seminar Series - March 28
Elaine Mardis presents at CCR Eminent Lecture
15th Annual CCR and DCEG Staff Scientist and Staff Clinician Retreat
Women Leaders in Biotech and Pharma Seminar Series
Datascience.cancer.gov: CBIIT’s new website for data science resources
Cancer Research Interns (CRI) available for summer placement in CCR labs
Check out CCR Central
April safety message
Bioinformatics Training and Education Program, Frederick
9th Annual NIH Women Scientist Advisors (WSA) Scholars Symposium
New course offering: Business of Science for Scientists
CCR Milestones 18-19
New study delivers chemotherapy to the liver for metastatic colorectal cancer patients
CCR staff receive funding from the Department of Defense
DNA Repair Interest Group Seminar
Stephanie Goff featured in an episode of The Doctors
New clinical trial will determine if gliomas respond to immunotherapy
Center of Excellence in Integrative Cancer Biology and Genomics: Advances in Cell Signaling Pathways in Cancer: From Biology to Therapeutics
GU Malignancies Seminar Series
12th Annual Frontiers in Chemistry and Biology Interface Symposium
Harnessing T-cell “stemness” could enhance cancer immunotherapy
Trial results show that younger lymphoma patients respond well to ibrutinib
Louis Staudt elected as a fellow of the AACR Academy
NCI CCR Liver Cancer Program Guest Speaker
New clinical trial recruits the immune system to attack chronic lymphocytic leukemia
CCR researchers discover how protein translation disruptions can lead to cancer
CCR Frederick Faculty Seminar Series
Christine Alewine - IRP podcast
Jaffe - honorary fellow royal college of pathology australasia
CCR Frederick Faculty Seminar Series
CCR FYI 19th Annual Colloquium
NIH Office of Research on Women's Health Facebook Live
NIH's 25th Annual Take Your Child to Work Day
CCR EMINENT LECTURE
Children's Inn Congressional Reception
Genomics Facebook Live
Women Leaders in Biotech and Pharma Seminar Series
CCR RNA Biology Initiative Seminar Series
Join the 2019 NIH Freezer Challenge
CCR Flex Awardees
Watch this new lab safety video
March Safety Message
2019 AACR Annual Meeting
FARE competition now open
Visit the new MyPART Website
Drug found effective in mice for uveal melanoma
DNA Repair Interest Group Seminar
Elaine Jaffe inducted as honorary fellow of the Royal College of Pathology of Australasia
CCR Presentations at AACR - 2019
From father to daughter: A bone marrow transplant for GATA2 deficiency
Deep-imaging study reveals extensive variability in 3D configuration of genomes between cells
Chalk Talks - Experiences from Successful Applicants
New strategy for treating brain tumors with mutations in metabolic enzymes
Recap: Grand Rounds with Felicia Knaul, Ph.D.
Researchers identify a key molecule that enhances T cell-based immunotherapy
Szent-Gyorgi Winner- Steve Rosenberg
Steve Rosenberg receives Szent-Györgi Prize for Progress in Cancer Research
Drug successfully treats WHIM syndrome
CCR Grand Rounds - March 8
Apply now: NIH-Duke Master’s in Clinical Research 2019-2020
CCR FREDERICK FACULTY SEMINAR SERIES - February 27
Grand Rounds with Felicia Knaul, Ph.D.
Announcing NCI-NIA and Curie-NCI awardees
CCR FREDERICK FACULTY SEMINAR SERIES - February 20
Kathy Warren, M.D., summits Mount Kilimanjaro
Seeking ideas for NIH Take Your Child to Work Day - April 25, 2019
CCR FREDERICK FACULTY SEMINAR SERIES - February 13
Call for proposals: NCI-UMD Partnership for Integrative Cancer Research
NIH's 25th Annual Take Your Child to Work Day
CCR WSA Coffee and Conversation
Combined Federal Campaign deadline extended
Eric Freed - American Academy of Microbiology fellow
NCI Director Ned Sharpless, M.D., looks to modernize clinical trials for cancer patients
Did you know? - Common Rule
Princess Chulabhorn Symposium in Thailand
FLC Award - Gulley, Bilusic, Madan, Hinrichs
CCR Staff Scientist and Staff Clinician Survey
Upgraded CCR Women’s Malignancies Branch and NIH websites
Gene mutations in Burkitt lymphoma hint at more effective treatment
Rising Stars Lecture Series seeks nominations
New video series
Building 538 Open House
CCR GRAND ROUNDS - February 22
Preparing for Science-Based Non-Traditional Careers workshop
NIH Workplace Climate & Harassment Survey launched
CCR staff receive NCI-NIA and Curie-NCI awards
Laboratory of Human Carcinogenesis - Notice of Seminar
New map of protein interactions hints at the underlying mechanisms of hereditary kidney cancer
New insights into mechanisms key to maintaining KRAS-mutant cancer cell survival
CBIIT Demo: Palantir Foundry Data Integration and Analysis Platform
DNA Repair Interest Group Seminar - February 19
Clinical trial studies antitumor effect of sunitinib in central nervous system sarcomas
Eric Freed elected fellow of the American Academy of Microbiology
Safety Message of the Month
Two new compounds target a cancer-promoting RNA transcript
Laboratory of Human Carcinogenesis Seminar - February 1
Clinical trial finds combination therapy effective for some biliary cancer patients
New imaging technology to detect early-stage hereditary diffuse gastric cancer tested in clinical trial
Second-generation maturation inhibitors show promise for HIV treatment
Arrica Wallace - Hinrichs Patient
Registration now open for Chromatin and Cell Fate Decisions in Development, Aging & Cancer
Steve Rosenberg receives 2019 Nathan Davis Award and Steinman Award
Watch new Neuro-Oncology Branch video on NCI YouTube
CCR Grand Rounds - February 1
OneDrive will soon be available to CCR staff
Watch the new Neuro-Oncology Branch video on YouTube
CCR FREDERICK FACULTY SEMINAR SERIES - January 30
Watch the new NCI-CONNECT video on YouTube
Directory of resources for researchers
New call for CAT-I proposals
Welcome to all new clinical fellows!
CCR Frederick Faculty Seminar Series - January 23
CCR FREDERICK FACULTY SEMINAR SERIES - January 16
Submission of Annual CY 2018 Report of Outside Activities
New funding opportunity: U.S.-China Program for Biomedical Collaborative Research
Patient education videos available on NCI YouTube
Rosenberg Nat Geo Article
CCR Frederick Faculty Seminar Series - January 9
2019 RNA Biology Symposium
February 11th is International Women and Girls in Science Day
Submit a proposal for FY19 single-year innovation funds for AIDS research
Come interview experienced summer & postbac students
CCR Center of Excellence in Immunology Seminar Series
Women Leaders in Biotech and Pharma Seminar
We want to feature you and your team!
Subscribe to our email updates
Did you know?
Steve Rosenberg awards
Arun Rajan senior clinician
Microsoft OneDrive Kiosk
Microsoft OneDrive Kiosk
CCR RNA Biology Initiative Seminar Series
CCR Women Scientist Advisors Coffee and Conversation
Milestones gallery recently installed in the CCR Office of the Director
Welcome to the new iCURE scholars
Mentor registration open for Werner H. Kirsten Student Intern Program
New reporting requirements for personal relationships in the workplace
CCR Grand Rounds - January 25
CCR Grand Rounds - January 11
Microsoft OneDrive Kiosk
NIH recognized as a best place to work
DNA Repair Interest Group Seminar
Glassdoor recognizes NIH as one of the best places to work
View the new NCI-CONNECT video on YouTube
In Memoriam: Stephen Katz, M.D., Ph.D.
Steve Rosenberg featured in National Geographic article on personalized medicine
Ken Kraemer discusses xeroderman pigmentosum with various media outlets
New CCR publication, Horizons, is now available
Clinical trials evaluate T-cell transfer therapy for cancers with a mutated KRAS gene
Sophisticated technology reveals gene expression in real time
Researchers create record-sized, integrated cellular cancer database
Registration is now open for the 2019 RNA Biology Symposium
Protein mutations lead to human disease by altering a cancer-promoting pathway
CCR FYI Holiday Gift Drive
Quarterly Meeting of the NCI Health & Safety Committee
Did you know?- IRB
NIH Clinical Center Gingerbread House Contest
Office of Research Nursing Holiday Celebration
Variant Analysis: SNVs, CNVs and Structural Variants in WGS and WE
New resource for Bioconductor open source bioinformatics software
Now accepting WALS nominations for the 2019-2020 season
2018 NCI Director's Awards Ceremony
Clinical Center unveils new video for patients
Mark Roschewski, senior clinician
Staff Scientist and Staff Clinician Professional Development Day
AHCJ Fellows Tour of the Clinical Center
Verify your phone lines before December 31
Combined Federal Campaign in full swing
Read CCR's newest publication, Horizons
DNA Repair Interest Group Seminar
19th Annual Colloquium Innovation and Discovery into Clinical Breakthroughs: Shaping the Future of Cancer Research
Discovery shows new circular RNAs linked to Kaposi sarcoma herpesvirus
In Memoriam: Valery Bliskovsky, Ph.D.
Clinical trial studies new therapy in children and adults with neurofibromatosis-related GIST
New immunotherapy clinical trial tests therapy for recurrent respiratory papillomatosis
CCR-FYI Holiday Gift Drive, November 26th – December 13th
Clinical trial tests safety and dosing of NEO-201 antibody in patients with advanced cancer
A novel mRNA modification may impact the human genetic code
Clinical trial tests customized treatment for ovarian cancer and peritoneal mesothelioma
Steven Rosenberg featured in The Wall Street Journal
Study provides evidence for theory on tumor evolution and its relationship to clinical outcomes
Clinical trial tests combination therapy for malignant mesothelioma
Renewed research focus on the human T-cell leukemia virus
World HTLV Day
Using near-infrared light to kill cancer cells in mice
DNA Repair Interest Group Seminar
Anti-diabetes drug impact on gut bacteria may offer clues to treating some metabolic diseases
Clinical All Hands meeting
Halloween trick or treating at the Clinical Center
Frederick Faculty Series - December 19
Frederick Faculty Series - December 12
New leadership for the NCI-Bethesda Animal Care and Use Committee (ACUC)
Dr. Alan Rabson Memorial
Liver cancer twitter live
Frederick Faculty Series - December 5
Frederick Faculty Seminar Series - November 28
Online NIH Technology Transfer training
Childhood cancer Facebook Live event
Participate in the #WhyIFightFlu campaign
CCR Grand Rounds - December 14
Updated NIH anti-harassment program
Kathy Warren and Caleb Joel
Jack Shern Lasker Scholar
WSA Coffee and Conversation
CCR Grand Rounds - December 7
2018 Annual NCI SS/SC Professional Development Day
Check out the new and improved CCR careers page
Excellence in Postdoctoral Research Training Award
New therapies tested in mice provide a one-two punch for treating liver cancer
Did you know?
Kathy Warren CBS news
Chris Kanakry Lasker
CCR Special Grand Rounds
November Safety Message
Germline and Somatic Mutation Analysis: Experimental Design, Variant Calling and Analysis
Apply for the 2019 AAAS Martin and Rose Wachtel Cancer Research Award
2019 Summer Internship Program changes
NICHD press release features new paper from CCR investigator Vanja Lazarevic
Christopher Kanakry appointed as an NIH Lasker Scholar Tenure Track Investigator
Jack Shern appointed as an NIH Lasker Scholar Tenure Track Investigator
Clinical trial evaluates small molecule inhibitor in von Hippel-Lindau disease-associated renal cell carcinoma
No Matter Who, What, When, Where, or Why
Clinical trial tests multiple targeted agents for treatment of non-Hodgkin lymphoma
Recap: The 5th NCI Pancreatic Cancer Symposium
Niral Shah, NPR Shots
did you know?
Barry O'Keefe ShareAmerica article
Expanded reimbursement for medical licensing expenses
Terri S. Armstrong Deputy Chief of NOB
German Minister of Health
CCR Congressional visit
CCR PowerPoint template slides available
October Safety Message
NCI Flow Cytometry Course
NCI and UMD Data Science Initiative Workshop
Request for proposals: Pfizer's Center for Therapeutic Innovation (CTI)
Moxetumomab Approved by FDA for Hairy Cell Leukemia
Bash Shell Scripting for Helix and Biowulf
Introduction to Linux
Former world-class hammer thrower battles diffuse large B-cell lymphoma (DLBCL)
Check out the new Pediatric Genomic Data Inventory
Sallie Rosen Kaplan (SRK) Postdoctoral Fellowship for Women Scientists
Chongyi Chen appointed as Stadtman Tenure Track Investigator
Andres Lebensohn appointed as Stadtman Tenure Track Investigator
National EAS and WEA Test
Clinical trial evaluates blood stem cell transplantation for patients with T-cell disorders
Study reveals function of protein crucial to survival of Staph infections
DNA Repair Interest Group Seminar
Take 3 Actions To Fight The Flu
Replace Smoke Alarms Every 10 Years!
Domestic Violence
Former world-class hammer thrower battles diffuse large B-cell lymphoma (DLBCL)
Kenneth Kraemer receives 2018 Environmental Mutagenesis and Genomics Society Award
precisionFDA
September is National Preparedness Month
Barry O’Keefe featured in ShareAmerica article
Naomi Taylor welcome party
Early-phase clinical trial to test new CAR T-cell therapy for multiple myeloma
Nirali Shah featured on follow-up NPR “Shots” blog post
Preparing Makes Sense In Any Language. Get Ready Now.
2018 Fall Frederick Faculty Seminar Series - October 31
2018 Fall Frederick Faculty Seminar Series - October 24
2018 Fall Frederick Faculty Seminar Series - October 10
2018 Fall Frederick Faculty Seminar Series - October 3
CCR Eminent Lecture - October 22
CCR Grand Rounds Lecture - October 19
CCR Grand Rounds Lecture - October 12
The Establishment and Control of Viral Persistence
Moxetumomab pasudotox becomes first FDA-approved drug for resistant hairy cell leukemia
CCR-FYI National Postdoc Appreciation Week Events
Soumen Roy, Hearing Health Foundation
Howard Young, Ruth L. Kirschstein Mentoring Award
Seventh Annual David Derse Memorial Lecture and Award
Lori Wiener, Rabson Award
CCR RNA Biology Workshop: 2018
Did you know? (FDA NIH collab for human gene therapy modernization)
Mark Roschewski, NIH Directors Awards
Signatures of Mutational Processes in Human Cancer-From Genomics to Etiology and Beyond
New location for CCR regulatory files
NIH Director's Awards CREx Team
2nd NCI Symposium on Cancer Health Disparities
Thank you for responding to FEVS!
Clinical All Hands Meeting
Christine M Heske, Children's Cancer Foundation funding
Cristina Bergamaschi, Milstein Young Investigator Award
September is National Preparedness Month
Before a Hurricane
CCR Office of Translational Resources
Sallie Rosen Kaplan (SRK) Postdoctoral Fellowship for Women Scientists Informational Session
Sallie Rosen Kaplan (SRK) Postdoctoral Fellowship for Women Scientists Informational Session
Conquer journal title pages in seconds
Center for Advanced Preclinical Research (CAPR)
Mandatory research ethics case study review now available
Fare Award Winner
CCR Camp Fantastic Twitter Takeover
NIH Research Festival
New funding opportunity - NCI and the Institut Curie
Elaine Jaffe to give Paulette Shirey Pritchett Endowed Lecture in Pathlogy
CCR Excellence in Postdoctoral Research Transition Award
Bacteria could promote lung cancer progression and be biomarkers for the disease
NIH Collaborative Research Exchange
Registration is now open for The Establishment and Control of Viral Persistence conference
CCR researchers receive Prostate Cancer Foundation’s 2018 Young Investigator Awards
DNA Repair Interest Group
Quarterly Meeting of the NCI Health & Safety Committee
Essential gene network suggests potential therapy for adult T-cell leukemia/lymphoma
Clinical trial tests immunotherapy combination for relapsed small cell lung cancer
Steve Rosenberg featured in STAT article
CCR-led research team develops predictor for immunotherapy response in melanoma
Nirali Shah featured on NPR “Shots” blog
Ped and bicyclists fatalities
New findings in Cell Stem Cell focus on Id1 and its effects on hematopoietic stem cells (HSCs)
Steve Rosenberg receives 2018 Albany Medical Center Prize in Medicine and Biomedical Research
DNA-damaging drugs show promise in helping treat dogs with lymphoma
Registration is now open for the 2018 CCR RNA Biology Workshop
Study reveals regions where harmful DNA breaks are most likely to occur
Special Grand Rounds
Digital screen requests
MobileIron
CIDP Media Screen
Prostate cancer journey leads to immunotherapy
John Schiller discusses HPV on iBiology video
NIH Pediatric & Wildtype GIST Clinic receives Jeroen Pit Science Award
New study characterizes protein’s role in regulating DNA replication in human cancer cells
Blocking MEK signaling pathway could inhibit rhabdomyosarcoma growth
Safety Message of the Month
Clinical trial studies benefit of targeted drug for malignant mesothelioma
Jing Wu appointed as an NIH Lasker Scholar
Kandice Tanner selected as Scialog Fellow
Norman Coleman receives 2018 Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care
Steven Pavletic elected as corresponding member of the Croatian Academy of Arts and Sciences
CAR T-cell therapy proves effective against multiple myeloma
Protein complex could be key to drug responsiveness in lymphoma patients
CCR: A history of advancing the field of immunology
CCR-FYI Colloquium
Save the Date: NCI Pancreatic Cancer Symposium
Frontiers in Basic Immunology
Clinical trial tests combinations of immunotherapy drugs for prostate cancer
Giorgio Trinchieri award
Pediatric Oncology Branch and other NCI staff host Congressional staff
CCR Clinical Excellence Awards
Did you know?
Changing hearts and minds: Improving outcomes in cancer treatment-related cardiotoxicity
CCR is looking for photographers
Facebook Live: Pediatric and Wildtype Gastrointestinal Stromal Tumor Clinic
Nominations open for STAT Wunderkinds
New CCR NCI Liver Cancer Program
New cryo-EM images provide blueprint for drug development
Clinical trial suggests moxetumomab pasudotox may be an effective treatment for hairy cell leukemia
Pediatric clinical trial supports use of selumetinib for children with neurofibromatosis type 1
Registration is now open for Frontiers in Basic Immunology: 2018 conference
Jack Shern ASCO award
Andrea Gross ASCO award
Registration now open for 5th NCI Pancreatic Cancer Symposium
Registration now open for 2nd NCI Symposium on Cancer Health Disparities
Steve Rosenberg receives the 2018 Jacobson Innovation Award of the American College of Surgeons
Steve Rosenberg featured in CBS News story profiling an immunotherapy clinical trial patient
Committing to cell division may be clue to cancer cell growth
Antibody-linked drug shrinks various types of tumors in preclinical study
Findings from clinical trial led by Steve Rosenberg published in Nature Medicine
Fighting a rare central nervous system tumor with research and optimism
Doug Lowy receives ASCO Science of Oncology Award and Lecture
Quarterly meeting of the NCI health & safety committee
Combination therapy for biochemically recurrent prostate cancer tested in new trial
CCR researchers receive ASCO Annual Meeting Merit Awards
25 years ago: CCR scientists discover first gene linked to kidney cancer
Clinical trial tests drug combination in mesothelioma of the lung or abdomen
Giorgio Trinchieri receives award from International Cytokine & Interferon Society
New study finds gut microbiome can control antitumor immune function in liver
S. Perwez Hussain tenured and promoted to Senior Investigator
Clinical trial investigates experimental drug for advanced pancreatic cancer
Facebook Live: Adult brain and spine tumor research and treatment
Misteli Mendel
Lowy and Schiller award
Selectively engaging immune responses may be key to fighting HIV infection
Eric Freed Receives Retrovirology Prize
Tim Greten Deputy
New trial engineers immune cells to treat solid tumors
Did you know?
New clinical trial uses targeted cancer drug for lymphatic system disease
Scientists develop potential new approach against cancer metastasis
Staff in action gallery
Don’t get locked out of your computer!
Sharpless town hall
CCR Landmarks
Animal care training for summer students
Important information for summer students
Thank a nurse this month!
Federal Employee Viewpoint Survey coming soon
Clinical trial tests first-in-class bifunctional immunotherapy drug in HPV-associated cancers
Joana Vidigal joins CCR as NIH Stadtman Investigator
Eros Lazzerini Denchi joins CCR as NIH Stadtman Investigator
Sergio Ruiz Macias joins CCR as NIH Stadtman Investigator
Doug Lowy and John Schiller receive Maryland Tech Council Lifetime Achievement Award
Trans-NIH RNAi Screening Facility
Apply now: Lasker Program
Tom Misteli delivers Mendel Medal Lecture at Mendel Lectures Series
Michael Gottesman elected to the National Academy of Sciences
Yousuke Takahama joins CCR as a Senior Investigator
Eric Freed receives 2018 KT Jeang Retrovirology Prize
CCR study wins Top 10 Clinical Research Achievement Award
New trial evaluates investigational drug for endometrial and breast cancers
FDA grants orphan drug status to selumetinib for neurofibromatosis type 1 (NF1) treatment
A physician faces her own ovarian cancer
Combination immunotherapy clinical trial for prostate cancer patients with rise in PSA
Activated platelets can promote tumor cell invasion into healthy tissue
New CCR publication, Landmarks, is now available
Focusing on function to mine cancer genome data
CCR Milestones 17-18
Our patients make it possible: Defeating Merkel cell carcinoma
Our patients make it possible: Defeating Merkel cell carcinoma
Our patients make it possible: Defeating Merkel cell carcinoma
Our patients make it possible: Defeating Merkel cell carcinoma
Study led by Louis Staudt revises molecular classification for most common type of lymphoma
Phase I clinical trial will test multi-targeted immunotherapy in common childhood cancer
Imaging technique predicts efficacy of targeting prostate tumor metabolism in mice
Marston Linehan featured in “The Code” video series from STAT and Retro Report
Study reveals potentially prognostic gene, metabolism changes in kidney cancers
New clinical trial studies drug combination for recurring ovarian cancer
New clinical trial tests prime-and-boost vaccine delivery for advanced solid tumors
CCR scientists to present at 2018 AACR Annual Meeting in Chicago
CCR celebrates Doctors Day
International Workshop on Merkel Cell Carcinoma Research (IWMCC) held in early March
New study shows normally helpful natural bacteria may also trigger lupus
CCR clinical trial patients featured in AFP article
AFP article profiles CCR’s Christian Hinrichs, a cancer survivor now leading clinical trials
CCR’s 2017-18 Milestones publication is now available
Defeating a rare, aggressive form of skin cancer with avelumab
Clinical trial uses combination therapy for certain types of non-Hodgkin lymphoma
Stem-cell technology rejuvenates cancer-fighting cells used in immunotherapy
Potential cancer immunotherapy drug shows promise against HIV
CCR-led study identifies possible strategy to improve efficacy of moxetumomab in leukemia
Doug Lowy receives Science of Oncology Award and Lecture from the American Society of Clinical Oncology
New clinical program will study metastatic colorectal cancer in viable patient tissue samples
Jeremy Davis featured in Wall Street Journal article on preventive surgery for stomach cancer
First bone marrow transplant for rare gene mutation made possible through CCR clinical trial
Former clinical trial patient featured on CBS This Morning
Novel technique used to treat melanoma and epithelial tumors in new clinical trial
Clinical trial aims to improve outcomes for children and young adults with primary brain tumors
Clinical trial helps pediatric patient build healthy immune system
First-in-human clinical trial evaluates safety of combination therapy to treat B-cell lymphomas
New collaborative study will explore health disparities for prostate cancer
Three CCR accomplishments receive Excellence in Technology Transfer Awards
Advanced and recurring thymic carcinoma is target of new clinical trial
Advanced and recurring thymic carcinoma is target of new clinical trial
Michael Gottesman receives the Dr. Nathan Davis Award for Outstanding Government Service
Doug Lowy and John Schiller receive the Szent-Györgyi Prize for Progress in Cancer Research
Pediatric patients featured in NIH Children’s Inn 2017 Annual Report
14th Annual CCR and DCEG Staff Scientist and Staff Clinician Retreat
18th Annual CCR Fellows and Young Investigators Colloquium
Promising drug target could restore immune system’s ability to fight HIV
CCR scientists help develop first recommendations for managing mesothelioma
Clinical trial tests new schedule of radiation therapy for recurring prostate cancer
Ken Aldape joins CCR as Chief, Laboratory of Pathology
Study characterizes how DNA-damaging anti-cancer drugs kill cancer cells
Pediatric Precision Oncology Conference
Clinical trial studies drug for pediatric diffuse intrinsic pontine glioma (DIPG) treatment
Phase II trial suggests new drug can shrink tumors in advanced ovarian cancer
Scientists repurpose HPV vaccine technology to fight eye cancer
Mark Roschewski discusses significance of early detection in solid tumors with Newsweek
Combination therapy for non-small cell lung cancer studied in new clinical trial
Yves Pommier named fellow of the American Association for the Advancement of Science
Michael Gottesman honored with Order of the Rising Sun by Japanese Government
New NCI video showcases one patient’s clinical-trial journey
Natalie Porat-Shliom joins CCR as NIH Stadtman Investigator
NBC4 interviews Foregut Team stomach-removal patient
Foregut team stomach-removal patient featured in The Washington Post
Foundation laid for understanding essentials of cell division
New clinical trial open for patients with muscle-invasive bladder cancer
Finding relief in the aftermath of Hurricane Maria: A patient’s journey from Puerto Rico to the National Institutes of Health
Thomas Waldmann named Fellow of the National Academy of Inventors
Molecular Biology in Single Cells Symposium
Two-Day Symposium - Frontiers in Targeting MYC: Expression, Regulation and Degradation
2018 RNA Interactions in Viral Infections Workshop
Anupama Khare joins CCR as NIH Stadtman Investigator
Researchers studying alternative to bladder removal for bladder cancer patients
CCR scientists featured in Cancer Special Report 2017 from Everyday Health
Walking with purpose after an HPV-related head and neck cancer diagnosis
Members of NIH Foregut Team discuss new treatment options for stomach cancer
Clinical trial tests precision radiotherapy for recurrent prostate cancer
New immunotherapy approach leads to remission in patients with the most common type of childhood cancer
Claudia Palena appointed as tenured senior investigator
Overactivating CAR T cells interferes with their ability to fight cancer in mice
Stephanie Goff receives American College of Surgeons Fellowship
Fearless in the face of small cell lung cancer
Why CCR: A conversation with Physician Assistant Julia Friend
Pediatric clinical trial studies antibody treatment for various types of solid tumors
Preclinical study shows drug has extreme potency against multidrug-resistant HIV variants
Clinical trial for patients with relapsed/refractory B-cell malignancies now recruiting
Haneen Shalabi receives The Children’s Cancer Foundation Next Gen Award
CCR researchers leading initiative to develop liquid biopsy technology
A novel imaging approach for prostate cancer is tested in new clinical trial
Serendipitous discovery in mice links inflammation directly to stroke
New clinical trial explores precision treatment for advanced pancreatic cancer
New clinical trial explores targeted therapy for three types of rare and aggressive lymphoma
Combination therapy for advanced or metastatic non-small cell lung cancer will be tested in new clinical trial
CCR clinical trial opens new door for pediatric cancer patient
New clinical trial aims to prevent breast cancer from recurring in the brain
CCR research lays foundation for FDA approval of CAR T cell therapy Yescarta
Researchers discover promising new targets for treatment of fatty liver disease
Shiv Grewal receives 2017 Indian National Science Academy Foreign Fellowship
Former CCR fellow named a 2017 STAT Wunderkind
Vassiliki Saloura appointed as Assistant Clinical Investigator
Watching the action unfold: New cryo-EM images capture CRISPR’s interaction with target DNA
CCR Celebrates National Postdoc Appreciation Week 2017
Efsun Arda appointed as NIH Stadtman Investigator
Recap: Lymphoma Twitter Chat for Blood Cancer Awareness and Childhood Cancer Awareness Month
Douglas Lowy and Nirali Shah discuss advancements in cancer treatment at the second annual Chasing Cancer Summit
Nicholas Restifo awarded 2018 ASM Award in Clinical and Diagnostic Immunology
Combination therapy clinical trial now recruiting patients with metastatic colorectal cancer
Clinical trial looks at new methods of assessing treatment response for esophageal cancer
CCR’s Douglas Lowy and John Schiller receive the 2017 Lasker~DeBakey Clinical Medical Research Award
Clinical trial will investigate targeted radionuclide therapy for inoperable rare tumors
Sriram Subramaniam named 2018 Biophysical Society Fellow
Clinical trial aims to study immunotherapy for central nervous system tumors
A fantastic camp experience for kids with unique health conditions
Recap: “First in Human” Twitter chat
CAR T-Cell therapy can lead to long-lasting remissions in patients with lymphoma
Kevin Camphausen awarded ASTRO Fellowship
Clinical trial tests drug for tumors associated with Krebs-cycle dysfunction
CCR scientists gain new understanding of cellular mechanisms during infection
NCI interns participate in NIH annual Summer Intern Poster Day
Freddy Escorcia appointed as Assistant Clinical Investigator
"First in Human" documentary features CCR physician-scientists
Keeping genome organized creates opportunities for damage
New study identifies essential genes for cancer immunotherapy
Trial opens to evaluate experimental cancer drug against solid tumors
New clinical trial will test immunotherapy for type of HPV infection
Anish Thomas appointed as new NIH Lasker Scholar
A protein in neuroblastoma could be a target of immunotoxins or immunotherapy
A new imaging technique to detect recurrent prostate cancer is tested in new clinical trial
Mark Gilbert discusses glioblastoma with Newsweek
Dysregulated RNA-binding proteins may skew tumor cells’ RNA levels and spur their growth
Study characterizes long non-coding RNA’s response to DNA damage in colon cancer cells
Center for Cancer Research hosts 10th Annual GIST Clinic
CCR researchers receive Prostate Cancer Foundation Young Investigator awards
Bacterial communities living on the skin of eczema patients vary with disease severity
Surgery Branch recruiting patients to study new treatment for cancers with RAS mutations
Using radioactive drugs could lead to better imaging of prostate cancer
POB/JHU trainee awarded Teaching Fellow of the Year
2nd International Gliomatosis Cerebri Working Group Conference
Molecular profiles suggest two types of liver cancer should be treated as one
New clinical trial studies the addition of immunotherapy to chemotherapy for patients with biliary tract carcinoma
New clinical trial studies therapy for Von Hippel-Lindau disease-associated kidney cancer
Researchers unmask secret to long-lasting effects of botulinum neurotoxin A in motor neurons
New clinical trial studies a new drug for mesothelin-positive lung cancer
A slow “catch and release” process prolongs immune attack on cancer cells
New combination therapy clinical trial opens for patients with metastatic or unresectable solid tumors
New clinical trial studies the immunotherapy drug pembrolizumab in patients with medullary thyroid cancer
Mark Roschewski awarded USPHS Research Physician of the Year
Registration open for "Cancer and Immunotherapy: From Conception to Delivery" symposium
Using the immune system to fight, and win, the battle against cervical cancer
Dr. LeBlanc featured in Colorado State and PBS documentary
Dr. Yarchoan elected to the Fellowship of the American Academy of Microbiology
In Memoriam: Peter Riesz, Ph.D., 1926 – 2017
Zbigniew Dauter receives Patterson Award from American Crystallographic Association
Clinical trial explores new glioblastoma treatment regimen
Not slowing down
A Conversation with Kristy and Jane
Clinical trial studies new therapy in children and adults with neurofibromatosis-related GIST
Richard Hodes receives Lifetime Achievement Award from the American Association of Immunologists
Researchers identify potential therapeutic targets for a rare childhood cancer
Clinical trial shows safety and effectiveness of new combination immunotherapy for advanced liver cancer
NCI RNA Biology 2017 symposium recap
New clinical trial studies two-part treatment for patients with gastric cancer
New clinical trial opens to determine safety and efficacy of PROSTVAC, nivolumab and ipilimumab in men with localized prostate cancer
Susan Gottesman receives Herbert Tabor Research Award
Hiroaki Mitsuya elected to Association of American Physicians
Structural map of Kaposi sarcoma-associated herpesvirus RNA provides clues to molecular interactions
Clinical trial studies a new form of vincristine in standard combination chemotherapy for children with relapsed ALL
New clinical trial studies immunotherapy and chemotherapy in Kaposi sarcoma herpesvirus-associated lymphomas
Center for Cancer Research plays key role in first FDA-approved drug for treatment of Merkel cell carcinoma
New clinical trial studies the use of avelumab in patients with recurrent thymoma and thymic carcinoma
New targets for immunotherapy-based treatment of HPV-related cancers
Steve Hughes awarded 2017 Distinguished Research Career Award from The Ohio State University Center for Retrovirus Research
Observational study of clinical and genetic nature of hereditary gastric cancers opens
Tom Uldrick discusses Castleman’s disease with The Huffington Post
Antibody-linked drug destroys tumor cells and tumor blood vessels in many types of cancer
New clinical trial to determine recommended dose of antibody when combined with sorafenib in patients with hepatocellular carcinoma (HCC)
Experimental immunotherapy shows promise in treating metastatic uveal melanoma
Pavlakis and Schiller inducted to National Academy of Inventors
CCR scientists tease out mechanisms of immune cell communication
In Memoriam: Claude Klee, M.D.
Investigators lead first human trials of new immunotherapy drug
New clinical trial opens to provide evaluation, tumor profiling and follow-up of patients with gastric tumors
AACR Honors Louis Staudt with Princess Takamatsu Memorial Lectureship
CCR presentations at AACR
“They gave me my life back”
Foregut cancers get new attention at CCR
Dr. Figg receives 2017 Tyler Prize for Stimulation of Research Award
New clinical trial studies if adding immunotherapy to standard of care improves outcomes for patients with metastatic colorectal cancer
New clinical trial studies immunotherapy for several types of lymphoma
New publication highlights 2016-2017 CCR research advances
Steve Rosenberg featured on CBS Sunday Morning
German Minister of Health and scientists tour Clinical Center
Study shows aspirin reduces the risk and recurrence of prostate cancer in African-American men
New study of safety and efficacy of combination therapy in patients with rhabdomyosarcoma
A teen’s participation in clinical trials inspires a career in science
In Memoriam: Amar J.S. Klar, Ph.D.
Safety and tolerability of combination therapy vs. standard treatment alone for patients with previously treated non-small cell lung cancer
Andrea Apolo discusses FDA approval of nivolumab
Clinical trial studies safety and efficacy of combined immunotherapies with different mechanisms of action in advanced tumors
Researchers uncover cause of genetic anomaly linked to cancer
Clinical trial shows new drug combo effective in prostate cancer treatment
Chuan Wu joins CCR as a Stadtman tenure track investigator
Conquer Cancer Foundation honors Farhad Fakhrejahani with a Genitourinary Cancers Symposium Merit Award
Genome sequencing of Ewing sarcoma patients reveals genetic predisposition
Sandra Wolin joins CCR as Chief, RNA Biology Laboratory
Terry Fry inducted into American Society of Clinical Investigation
Low-grade prostate tumors can harbor signs of aggressive cancer
Congressional members visit CCR
Steven Rosenberg featured on NBC's Today show
World Cancer Day
Registration now open for the 2017 NCI RNA Biology Symposium
Dr. Zhengping Zhuang appointed as senior investigator
Registration now open for the Metastatic Niche Symposium!
A phase II study tests a new drug for patients with advanced thyroid cancer
William Dahut leads discussion of prostate cancer treatment options
Dr. Alex Compton appointed as tenure track investigator
Christian Hinrichs discusses cancer research with PBS NewsHour’s Hari Sreenivasan
Novel target for high-risk neuroblastoma identified in pre-clinical research
Molecules discovered that block cancer-associated microRNAs
Brigitte Widemann leads early-phase trial that shows drug shrinks NF1 tumors
Dr. Frank Lin appointed as Lasker Clinical Research Scholar
Potential treatment for radiation-induced lung injury identified
A crucial step in cell division identified
Chemotherapy drug shuts down cell growth by triggering a natural checkpoint
Minimizing hazards associated with cancer vaccines
New York Times features patient in Rosenberg’s immunotherapy trial
Cellular immunotherapy targets a common human cancer mutation
Edward Cowen discusses dermatology minerals on display at the NIH-Smithsonian exhibit
Roberto Weigert produces Celldance video for ASCB 2016 Annual Meeting
Rosenberg featured as Cancer Research Pioneer
New study tests the safety and efficacy of combination therapy in adults with astrocytoma and glioblastoma
Dr. Terri Armstrong appointed as senior investigator
Dr. Jagan Muppidi appointed as tenure track investigator
Dr. Pedro Jorge Batista appointed as tenure track investigator
Dr. Merlino elected as AAAS Fellow
Brigitte Widemann selected as Chief, Pediatric Oncology Branch
Andrea Apolo discusses why patients are never forgotten
Clinical Research Center welcomes first-ever National Cancer Reporting Fellowship
Structural biologists capture detailed image of gene regulator’s fleeting form
Lori Wiener discusses psychosocial impacts of childhood cancers
New clinical trial tests safety and efficacy of combination therapy in ovarian cancer and other women's malignancies
Team identifies potential marker of resistance to PARP inhibitor drugs
MPNST state of the science: outlining a research agenda for the future
Over 200 people attended the first Cancer Health Disparities Interest Group Research Symposium on October 18th
NIMHD/NCI CCR Eddie Reed Mini-Symposium
Fighting liver cancer with combination immunotherapies
Brigitte Widemann receives Humanitarian Award at Children’s Tumor Foundation Gala
Christina Annunziata discusses PARP inhibitors with STAT
Howard Young named Honorary Life Member of International Cytokine and Interferon Society
Conference to showcase the latest findings on emerging viral pathogens
New insights into the dual role of TGF-beta
Jung-Min Lee discusses ovarian cancer study results with The ASCO Post
Liver disease stage determines whether the immune response stifles or stimulates tumor growth
Cracking the finger code: an interview with CCR’s Susan Mackem
CCR investigator describes the use of HeLa cells in cancer research
8-year-old girl in remission after immunotherapy clinical trial
Experimental drug STA-8666 causes complete tumor regression in animal models of pediatric sarcomas
CCR celebrates Childhood Cancer Awareness Month
Possible new treatment for Kaposi sarcoma
Genome organization factor determines the few cells that make a tumor grow
Clinical trial combines drugs with or without Celecoxib to reactivate genes in lung metastases
ETIB opens clinical trial for patients with HPV-16+ cancers
ETIB tests safety and effectiveness of Baricitinib for chronic GVHD
Eliminating cancer stem cells: an interview with CCR’s Steven Hou
Swedish Minister for Higher Education & Research visits CCR investigators in Clinical Center
The answer to cancer may be walking beside us
CCR celebrates National Postdoc Appreciation Week
Thomas Uldrick discusses new immunotherapy trial in Cancer Today magazine
Kent Hunter’s circadian gene research highlighted across national news
Steven Pavletic discusses new strategies to target GVHD
A non-small cell lung cancer clinical trial is recruiting to study benefit of Osimertinib/tagrisso after local ablative therapy
NCI Cancer Health Disparities Interest Group presents the first NCI Symposium on Cancer Health Disparities
NCI Symposium on Chromosome Biology to bring together internationally renowned experts in the fields of chromosome structure and function
NCI-UMD Partnership for Integrative Cancer Research holds first meeting
High levels of potassium inside tumors suppress immune activity
Six-year-old Jordan fights thyroid cancer with the help of the Pediatric Oncology Branch
Two-day national symposium will address recent advances in the field of cancer and inflammation
Targeting DNA repair proteins shown to prevent and shrink tumors
Rare Tumors Initiative Symposium brings together international experts on malignant peripheral nerve sheath tumors (MPNST)
New clinical trial will test COXEN’s ability to choose best therapy for patients with advanced bladder cancer
Dr. Amy LeBlanc quoted in Proto magazine article
NIH featured on Universum’s most attractive employers list
Study finds gene expression classifier for early stage squamous cell carcinoma
Steven Rosenberg discusses immunotherapy on “What it Takes” podcast series
Study finds remarkable synergy between immunotoxins and actinomycin D
4th NCI-Pancreatic Cancer Symposium
Dr. Jonathan Hernandez appointed as tenure track investigator
Immunologists to share cutting-edge discoveries at annual workshop
Tumor DNA in blood may signal response to T-cell transfer immunotherapy
Distinguished investigator Shiv Grewal discusses heterochromatin assembly
New phase II trial of avelumab, a PD-L1 inhibitor, in recurrent respiratory papillomatosis
Clinical trial studies safety and efficacy of adding a kinase inhibitor to chemotherapy with topotecan in small cell lung cancer
September is Childhood Cancer Awareness Month
CCR researcher finds oxygen can impair cancer immunotherapy in mice
Dr. Ping Zhang appointed as tenure track investigator
Waldmann discusses the "the second coming of daclizumab"
Blood-brain barrier: the "Holy Grail' of neuro-oncology
Dr. Ramaprasad Srinivasan appointed as tenure track investigator
Seeking to unlock the genomic keys to ovarian cancer
Faith, hope, and determination help teenager fight a rare cancer
Clinical trials on pets moving cancer research forward
New immunotherapy gives tumor-fighting immune cells the chance to attack
“Scientific pioneer”: Steven Rosenberg honored with Novartis Prize in Immunology
Tanner named as one of the 2016 Young Innovators of Cellular and Molecular Bioengineering
Ramiro Iglesias-Bartolome joins CCR as a Stadtman Investigator
PARP inhibitors may affect normal cells in patients with a BRCA mutation
New clinical trial to study long-term progression of brain and spine cancers
Little patients are our biggest heroes
Uncovering molecular targets for personalized treatment at CCR
Use of low-dose chemo with CAR T cells to treat advanced lymphoma
Serial killers on the loose
Kieron Dunleavy featured by ASCO Pan Pacific Lymphoma Conference
Wyndham Wilson featured by ASCO Pan Pacific Lymphoma Conference
Incredibly exciting time in cancer treatment
New technology precisely measures DNA breaks in vivo: an interview with CCR’s Andre Nussenzweig
CCR study: evidence for benefit of TARP vaccine for men with early stage prostate cancer
Ira Pastan discusses his latest research on immunotoxins targeting mesothelin
Clinical trial studies combination effect on small cell lung cancer
Liz Ness receives the 2016 Distinguished Alumni Award from the University of Maryland School of Nursing
Dr. Jing Huang receives tenure
Dr. Christine Alewine appointed as a Lasker Investigator
Dr. Subramaniam discusses using new high-tech microscopes in cancer research
CCR team uncovers a new principle in chemotherapy resistance in breast cancer
CURE magazine honors CCR nurse Cindy Delbrook as “an extraordinary healer”
Dr. Jung-Min Lee appointed as Lasker Scholar Investigator
Clinical trial combines enzalutamide with immunotherapy for advanced prostate cancer
New clinical trial combines LMB-100 with nab-paclitaxel for metastatic or locally advanced pancreatic cancer
CCR researchers find DNA-binding triggers tetramerization of glucocorticoid receptor in live cells
CCR investigators use liquid biopsies to uncover cancer in the blood of lymphoma patients
New developments in active surveillance for prostate cancer
John Brognard joins CCR as a Stadtman Investigator
MOL highlight: cryo-EM analysis of the conformational landscape of human P-glycoprotein (ABCB1) during its catalytic cycle
CCR researchers show that blocking the estrogen receptor restores the sensitivity of lung cancer cells to therapy
CCR researchers provide insight into pathway that initiates a common type of skin cancer
CCR researchers identify pathway critical for preventing premature aging
Trial of Pembrolizumab for HIV-Positive Patients with Recurrent or Refractory Cancer
Study Visualizes Proteins Involved in Cancer Cell Metabolism
Get cozy with your skin bacteria — they're not going anywhere
Cancer Survivors Day
June is Cancer Immunotherapy Awareness Month
Adjuvant-Specific Genetic and Immune Signatures Associated with Lower SIV Infection Risk in Animal Models
MIF Drives Pancreatic Cancer Aggressiveness by Downregulating NR3C2
Antisense Oligonucleotide Therapy for Patients with Advanced Cancer
New Treatment Target Identified for Diffuse Large B-Cell Lymphoma
10 questions with NIH senior investigator Howard Young
BRD4 Regulates Transcription via Intrinsic HAT Activity
Dr. Ira Daar appointed co-chief of Cancer and Developmental Biology Laboratory
We Do Cancer Research Like Nobody Else
A different approach to explaining environment and accident in causing cancer
Dr. Linehan to receive the 2016 Ramon Guiteras Award
Norman Coleman Receives 2016 Failla Award
Yinling Hu, Ph.D. Receives Tenure
Young Fluorescence Investigator Award Goes to Tanner
Robert Yarchoan Elected to Association of American Physicians
Michael Lichten elected to AAAS
Novel Genome-Wide Screening Method Identifies Genes Important to Breast Cancer Metastasis
Brachyury Essential for Notochord Cell Fate, Not Proliferation or EMT
Honoring our past SAMMIE winners
Targeted Photoimmunotherapy Approach for Cancer Moves Forward
Childhood Cancer Talk Radio interviews Dr. Kathy Warren
Dynamic Regulation of FoxA1 by Steroid Receptors
Celebrate Diversity Month
Celebrating Women's History Month
RNA Processing is a Potential Therapeutic Target in Ewing Sarcoma
Selective CD4+ T Cell Loss Promotes Liver Cancer Development
Early Clinical Trial Results of New Targeted Ovarian Cancer Therapy
Histone Variant H2A.X Regulates Colon Cancer EMT
Surprising Loss of Symmetry of Magnesium Channel CorA Upon Gating
Cancer drug target visualized at atomic resolution
Gene Positioning as a Diagnostic Marker in Prostate Cancer
Insight into Prostate Cancer Stem Cells
Naïve-Derived T Cell Adoptive Immunotherapy is Impaired by Memory T Cells
Understanding Papillary Renal Cell Carcinoma
Salem Malikic, Ph.D.
Sung-Yun Pai, M.D.
Shan Li, Ph.D.
Tanya Grkovic, Ph.D.
Lin Du, Ph.D.
Kazusa Ishii, M.D., M.P.H.
Philippe Youkharibache, Ph.D.
Acong Yang, Ph.D.
Srivandana Akshintala, MBBS, MPH
Lipika Ray, Ph.D.
Lekha Mikkilineni, M.D.
Michael B. Aregger, Ph.D.
Noa G. Holtzman, M.D.
Mary Frances Wedekind Malone, M.D.
Jinkyu Jung, Ph.D.
Matthew T. Wolf, Ph.D.
Paden King, Ph.D.
Prachi Mishra, Ph.D.
Travis H. Stracker, Ph.D.
Colin C. C. Wu, Ph.D.
Wei Tang, Ph.D.
Brian A. Lewis, Ph.D.
Rupali Sharma, Ph.D.
Caroline Jochems Frohlich, M.D., Ph.D.
Thomas Gonatopoulos-Pournatzis, Ph.D.
Sadhana Jackson, M.D.
Brian J. Capaldo, Ph.D.
Ryan M. Young, Ph.D.
Andrew M. Blakely, M.D.
Christian T. Mayer, Ph.D.
Javier Gonzalez Alarcon, M.D.
Lea C. Cunningham, M.D.
Christina I. Schroeder, Ph.D.
Munjid Al Harthy, M.D.
Esther Mena, M.D.
Erin L. Davies, Ph.D.
Sun Woo Sophie Kang, Ph.D.
Bau-Lin Huang, Ph.D.
Vanja Lazarevic, Ph.D.
Benedict Anchang, Ph.D.
Cecilia Monge, M.D., M.P.H., FACP
Scot Niglio, M.D., M.S.
David Takeda, M.D., Ph.D.
Heather E. Leeper, M.D., M.S.
Chen Zhao, M.D.
Jaeho Yoon, Ph.D.
Nitin Roper, M.D., M.Sc.
Charalampos Floudas, MD, DMSc, MS
Laurie T. Krug, Ph.D.
Martha A. Zeiger, M.D.
Euna Yoo, Ph.D.
Eugene Valkov, Ph.D.
E. Michael Gertz, Ph.D.
Changqing Xie, M.D., Ph.D.
Christopher J. Ricketts, Ph.D.
Sudheer Kumar Gara, Ph.D.
Nicolas Çuburu, Ph.D.
Jason M. Redman, M.D.
Sridhar Hannenhalli, Ph.D.
Peng Jiang, Ph.D.
S. Cenk Sahinalp, Ph.D.
Alejandro A. Schäffer, Ph.D.
Gabriel J. Starrett, Ph.D.
Julián Candia, Ph.D.
Giorgio Trinchieri, M.D.
Meghan Bell, B.S.
Vladimir A. Valera Romero M.D., Ph.D.
Eric C. Burton, M.D.
Andrea M. Gross, M.D.
Hao-Wei Wang, M.D., Ph.D.
Anand Singh, Ph.D.
Marta Penas-Prado, M.D.
Nathanael D. Pruett, Ph.D.
Lanqing Ying, Ph.D.
James P. Madigan, Ph.D.
Azam Ghafoor, M.D.
Joshua A. Welsh, Ph.D.
Andres M. Lebensohn, Ph.D.
Chongyi Chen, Ph.D.
Haneen Shalabi, D.O.
Jeremy Rose, M.S.
Houssein Abdul Sater, M.D.
David A. Ball, Ph.D.
Kirsten Remmert, Ph.D.
Naomi Taylor, M.D., Ph.D.
Samira M. Sadowski, M.D.
Ramya Ramaswami, M.B.B.S., M.P.H.
Kathryn A. Lurain, M.D., M.P.H.
Jennifer N. Brudno, M.D.
Daniel Feliciano, Ph.D.
Megan Stefkovich, B.S.
Scott M. Norberg, D.O.
William G. Telford, Ph.D.
Joana A. Vidigal, Ph.D.
Surajit Sinha, Ph.D.
Imani Alexander
Sergio Ruiz Macias, Ph.D.
Yousuke Takahama, Ph.D.
Eros Lazzerini Denchi, Ph.D.
Sabrina Lusvarghi, Ph.D.
Dan Shi, Ph.D.
Sukbir Kaur, Ph.D.
Jennifer Clare Jones, M.D., Ph.D.
Mark W. Ball, M.D.
Kenneth Aldape, M.D.
Eytan Ruppin, M.D., Ph.D.
Jaydira Del Rivero, M.D.
Natalie Porat-Shliom, Ph.D.
Fatima Karzai, M.D.
Milos Miljković, M.D., M.Sc.
H. Efsun Arda, Ph.D.
Vassiliki Saloura, M.D. Ph. D.
Marielle E. Yohe, M.D., Ph.D.
Steven D. Cappell, Ph.D.
Freddy E. Escorcia, M.D., Ph.D.
Dickran G. Kazandjian, M.D.
Hoyoung M. Maeng, M.D.
Xinguo Chen, Ph.D.
Anupama Khare, Ph.D.
Christopher J. Melani, M.D.
H. Diego Folco, Ph.D.
Scott Walsh, Ph.D.
Joseph Chinquee, DHSc, MBA, MT(ASCP)DLM
Fedor Kouzine, Ph.D.
Caiyi Cherry Li, Ph.D.
Sofia R. Gameiro, Ph.D.
Renee N. Donahue, Ph.D.
Orit Lavi, Ph.D.
Stefania Pittaluga, M.D., Ph.D.
Julius Strauss, M.D.
Chuan Wu, M.D., Ph.D.
Sandra L. Wolin, M.D., Ph.D.
Zhengping Zhuang, M.D., Ph.D.
Alex Compton, Ph.D.
Frank I. Lin, M.D.
Pedro J. Batista, Ph.D.
Terri S. Armstrong, Ph.D., ANP-BC, FAAN, FAANP
Jagan R. Muppidi, M.D., Ph.D.
Lixin Fan, Ph.D.
Chengkai Dai, Ph.D.
Jonathan M. Hernandez, M.D.
Hiroshi Matsuo, Ph.D.
Matthew J. Anderson, Ph.D.
Ping Zhang, Ph.D.
Duane H. Hamilton, Ph.D.
Yun Ji, Ph.D.
Ramiro Iglesias-Bartolome, Ph.D.
Haobin Chen, M.D., Ph.D.
Christine M. Heske, M.D.
Keqiang Chen, Ph.D.
John Brognard, Ph.D.
Marijo Bilusic, M.D., Ph.D.
Murali Palangat Ph.D.
Michael L. Beshiri, Ph.D.
Supreet Agarwal, Ph.D.
Ivy Yin, Ph.D.
Prabhakar R. Gudla, Ph.D.
John J. DiGiovanna, M.D.
Ferenc Livak, M.D.
Yoo-Seok (Rich) Hwang, Ph.D.
Richard M. Sherry, M.D.
Jianjian Zhu, Ph.D.
Ravi B. Chalamalasetty, Ph.D.
Subhadra Banerjee, Ph.D.
Elsa Callen Moreu, Ph.D.
Ross Lake
Jing Wu, M.D., Ph.D.
Noriko Sato, M.D., Ph.D.
Elaine M. Jagoda, M.S.
Sam John, Ph.D.
Alexandra S. Zimmer, M.D.
Grégoire Altan-Bonnet, Ph.D.
Richard F. Little, M.D.
Chunzhang Yang, Ph.D.
Songjoon Baek, Ph.D.
Mioara Larion, Ph.D.
Jack F. Shern, M.D.
Janusz W. Koscielniak, Ph.D.
Adam Sowalsky, Ph.D.
Nataliya P. Buxbaum, M.D.
Brad Wood, M.D.
Mary E. Pitman, B.S.
Jennifer A. Kanakry, M.D.
Jeremy L. Davis, M.D.
Daniël P. Melters, Ph.D.
Roberto Weigert, Ph.D.
Amy K. LeBlanc, D.V.M.
Christopher G. Kanakry, M.D.
Yue Hu, Ph.D.
Darawalee Wangsa Zong, Ph.D.
Balamurugan Kuppusamy, Ph.D.
Elizabeth A. Conner, Ph.D.
Romina Goldszmid, Ph.D.
Jonathan H. Badger, Ph.D.
Chuong D. Hoang, M.D.
Sima Zadeh Bedoya, PsyD
Meera Murgai, Ph.D.
Genbin Shi, Ph.D.
Eva Dombi, M.D.
John W. Glod, M.D., Ph.D.
Mary Anne Toledo-Tamula, M.A.
Xiang Chen, Ph.D.
Mark R. Gilbert, M.D.
Zhihui Liu, Ph.D.
Avinash Bhandoola, M.B., B.S., Ph.D.
Brad St. Croix, Ph.D.
Jason R. Stagno, Ph.D.
Louis M. Staudt, M.D., Ph.D.
Diana A. Stavreva, Ph.D.
Patricia S. Steeg, Ph.D.
Esta Sterneck, Ph.D.
Maryalice Stetler-Stevenson, M.D., Ph.D.
William G. Stetler-Stevenson, M.D., Ph.D.
Jeffrey N. Strathern, Ph.D.
Christina H. Stuelten, M.D., Ph.D.
David M. Sturgill, Ph.D.
Yongjun Sui, Ph.D.
Wenyue Sun, Ph.D.
Chin-Hsien (Emily) Tai
Binwu Tang, Ph.D.
Kandice Tanner, Ph.D.
Sergey G. Tarasov, Ph.D.
Nadya I. Tarasova, Ph.D.
Masaki Terabe, Ph.D.
Lino Tessarollo, Ph.D.
Carol J. Thiele, Ph.D.
Anish Thomas, MBBS, M.D.
Craig J. Thomas, Ph.D.
Lynn Thomason, Ph.D.
Philip Tofilon, Ph.D.
Giovanna Tosato, M.D.
Jane B. Neckers
Joseph E. Tropea, Ph.D.
Ismail Baris Turkbey, M.D.
Julio C. Valencia, M.D.
Lyuba Varticovski, M.D.
Mathias Viard, Ph.D.
Charles R. Vinson, Ph.D.
Cathy D. Vocke, Ph.D.
Abdul A. Waheed, Ph.D.
Lalage M. Wakefield, D.Phil.
Thomas A. Waldmann, M.D.
Kylie J. Walters, Ph.D.
Ji Ming Wang, M.D., Ph.D.
Xin Wei Wang, Ph.D.
Yun-Xing Wang, Ph.D.
David S. Waugh, Ph.D.
Jun S. Wei, Ph.D.
Jonathan M. Weiss, Ph.D.
Allan M. Weissman, M.D.
Christopher J. Westlake, Ph.D.
Sue Wickner, Ph.D.
Brigitte C. Widemann, M.D.
Lori Wiener, Ph.D., DCSW, LCSW-C
Wyndham Wilson, M.D., Ph.D.
David A. Wink Jr., Ph.D.
Cheryl Ann Winkler, Ph.D.
Alexander Wlodawer, Ph.D.
Karen M. Wolcott
Girma M. Woldemichael, Ph.D.
Pamela L. Wolters, Ph.D.
Carl Wu, Ph.D.
Liqiang Xi, M.D.
Di Xia, Ph.D.
Terry P. Yamaguchi, Ph.D.
De Yang, M.D., Ph.D.
Howard H. Yang, Ph.D.
James C. Yang, M.D.
Li Yang, Ph.D.
Robert Yarchoan, M.D.
Howard A. Young, Ph.D.
Yan Lin Yu, Ph.D.
Constance M. Yuan, M.D., Ph.D.
Stuart H. Yuspa, M.D.
Shuling Zhang, M.D., Ph.D.
Ying E. Zhang, Ph.D.
Xue Zhi Zhao, Ph.D.
Zhi-Ming Zheng, M.D., Ph.D.
Victor B. Zhurkin, Ph.D.
Joseph M. Ziegelbauer, Ph.D.
Ruth Nussinov, Ph.D.
Shalini Oberdoerffer, Ph.D.
Colm S. O'Huigin, Ph.D.
Barry R. O'Keefe, Ph.D.
Masanori Onda, M.D., Ph.D.
Joost J. Oppenheim, M.D.
Svetlana D. Pack, Ph.D.
Claudia M. Palena, Ph.D.
Jung-Eun Park, Ph.D.
Jung-Hyun Park, Ph.D.
Maria R. Parkhurst, Ph.D.
Ira Pastan, M.D.
Bruce M. Paterson, Ph.D.
Vinay K. Pathak, Ph.D.
Gary T. Pauly, Ph.D.
George N. Pavlakis, M.D., Ph.D.
Steven Z. Pavletic, M.D., M.S.
Gianluca Pegoraro, Ph.D.
Alan O. Perantoni, Ph.D.
Liyanage P. Perera, Ph.D.
Staci Martin Peron, Ph.D.
James M. Phang, M.D.
Peter A. Pinto, M.D.
Miriam C. Poirier, Ph.D.
Yves Pommier, M.D., Ph.D.
Douglas K. Price, Ph.D.
Anu Puri, Ph.D.
Xiaolan Qian, M.D., Ph.D.
Mark Raffeld, M.D.
Arun Rajan, M.D.
Kumaran S. Ramamurthi, Ph.D.
Paul A. Randazzo, M.D., Ph.D.
Jason W. Rausch, Ph.D.
Christophe E. Redon, Ph.D.
Karlyne M. Reilly, Ph.D.
Alan Rein, Ph.D.
William C. Reinhold, B.S.
Lisa Ann Ridnour, Ph.D.
Thomas Ried, M.D.
Paul F. Robbins, Ph.D.
Marjorie Robert-Guroff, Ph.D.
David D. Roberts, Ph.D.
Paul A. Roche, Ph.D.
Mark Roschewski, M.D.
Anna V. Roschke, Ph.D.
Steven A. Rosenberg, M.D., Ph.D.
Udo Rudloff, M.D., Ph.D.
Brid M. Ryan, Ph.D., M.P.H.
Rosalba Salcedo, Ph.D.
David S. Salomon, Ph.D.
Lawrence E. Samelson, M.D.
John T. Schiller, Ph.D.
Jeffrey Schlom, Ph.D.
Laura S. Schmidt, Ph.D.
John 'Jay' Schneekloth Jr., Ph.D.
Joel P. Schneider, Ph.D.
Thomas D. Schneider, Ph.D.
Martin J. Schnermann, Ph.D.
David S. Schrump, M.D., M.B.A.
Arthur L. Shaffer III, Ph.D.
Nirali N. Shah, M.D., M.H.Sc.
Uma T. Shankavaram, Ph.D.
Bruce A. Shapiro, Ph.D.
Shyam K. Sharan, Ph.D.
Susan O. Sharrow, B.S.
R. Mark Simpson, D.V.M., Ph.D.
Alfred Singer, M.D.
Dinah S. Singer, Ph.D.
Tristan Sissung, Ph.D., M.S.
DeeDee K. Smart, M.D., Ph.D.
Ramaprasad Srinivasan, M.D., Ph.D.
James A. Kelley, Ph.D.
Alexander E. Kelly, Ph.D.
Kathleen Kelly, Ph.D.
Vineet N. KewalRamani, Ph.D.
Javed Khan, M.D.
Sikandar G. Khan, Ph.D.
Shioko Kimura, Ph.D.
David E. Kleiner, M.D., Ph.D.
Dennis M. Klinman, M.D., Ph.D.
Hisataka Kobayashi, M.D., Ph.D.
James N. Kochenderfer, M.D.
Kurt W. Kohn, M.D., Ph.D.
Damian Kovalovsky, Ph.D.
Kenneth H. Kraemer, M.D.
Robert J. Kreitman, M.D.
Michael J. Kruhlak, Ph.D.
Ashish Lal, Ph.D.
Vladimir L. Larionov, Ph.D.
Daniel R. Larson, Ph.D.
Stuart F.J. Le Grice, Ph.D.
Byungkook Lee, Ph.D.
Chyi-Chia Richard Lee, M.D., Ph.D.
Jung-Min Lee, M.D.
KyeongEun Lee, Ph.D.
Kyung S. Lee, Ph.D.
Maxwell P. Lee, Ph.D.
David L. Levens, M.D., Ph.D.
Jason E. Levine, M.D.
Mark B. Lewandoski, Ph.D.
Luowei Li, Ph.D.
Wenqing Li, Ph.D.
Michael Lichten, Ph.D.
P. Charles Lin, Ph.D.
M. Liza Lindenberg, M.D.
W. Marston Linehan, M.D.
Stanley Lipkowitz, M.D., Ph.D.
Zheng-Gang Liu, Ph.D.
Jadranka Loncarek, Ph.D.
George T. Lountos, Ph.D.
Douglas R. Lowy, M.D.
Jacek Tadeusz Lubkowski, Ph.D.
Ji Luo, Ph.D.
Ruibai Luo, Ph.D.
Susan Mackem, M.D., Ph.D.
Ravi A. Madan, M.D.
Nadim Majdalani, Ph.D.
Frank Maldarelli, M.D., Ph.D.
Victor E. Marquez, Ph.D.
Maureen P. Martin, M.D.
Michael Maurizi, Ph.D.
Katherine M. McKinnon
Daniel W. McVicar, Ph.D.
Jordan L. Meier, Ph.D.
Paul S. Meltzer, M.D., Ph.D.
Maria J. Merino, M.D.
Glenn Merlino, Ph.D.
Aleksandra M. Michalowski, M.Sc., Ph.D.
Markku Martti Miettinen, M.D., Ph.D.
Stavroula Mili, Ph.D.
Maria Miller, Ph.D.
Robert William Miller, Ph.D.
Tom Misteli, Ph.D.
James B. Mitchell, Ph.D.
Hiroaki Mitsuya, M.D., Ph.D.
Beverly Mock, Ph.D.
Maria I. Morasso, Ph.D.
Deborah K. Morrison, Ph.D.
Kathrin Muegge, M.D.
Leonard M. Neckers, Ph.D.
Marc C. Nicklaus, Ph.D.
Naris Nilubol, M.D., F.A.C.S.
Andre Nussenzweig, Ph.D.
Wendy D. DuBois
Scott K. Durum, Ph.D.
Daniel C. Edelman, Ph.D.
Barbara K. Felber, Ph.D.
Hanqiao Feng, Ph.D.
William Douglas Figg Sr., Pharm.D.
Armando Filie, M.D.
David J. FitzGerald, Ph.D.
Francis A. Flomerfelt, Ph.D.
Genoveffa Franchini, M.D.
Eric O. Freed, Ph.D.
Jeffrey C. Gildersleeve, Ph.D.
Stephanie L. Goff, M.D.
Frank J. Gonzalez, Ph.D.
Michael M. Gottesman, M.D.
Susan Gottesman, Ph.D.
Yoshimi Endo Greer, M.D., Ph.D.
John W. Greiner, Ph.D.
Ronald E. Gress, M.D.
Tim F. Greten, M.D.
Shiv Grewal, Ph.D.
Brunilde M. Gril, Ph.D., M.P.S.
Shuo Gu, Ph.D.
James L. Gulley, M.D., Ph.D.
Alla Gustchina, Ph.D.
Gordon L. Hager, Ph.D.
Ken-ichi Hanada, M.D., Ph.D.
Curtis C. Harris, M.D.
Raffit Hassan, M.D.
Curtis J. Henrich, Ph.D.
Kerstin Heselmeyer-Haddad, Ph.D.
Stephen M. Hewitt, M.D., Ph.D.
Dennis D. Hickstein, M.D.
Christian S. Hinrichs, M.D.
Mitchell Ho, Ph.D.
Richard J. Hodes, M.D.
James W. Hodge, Ph.D., M.B.A.
Izumi Horikawa, M.D., Ph.D.
Wei-Shau Hu, Ph.D.
Yinling Hu, Ph.D.
Jing Huang, Ph.D.
Stephen H. Hughes, Ph.D.
Kent W. Hunter, Ph.D.
S. Perwez Hussain, Ph.D.
Elaine S. Jaffe, M.D.
Lisa M. Jenkins, Ph.D.
Xinhua Ji, Ph.D.
Peter F. Johnson, Ph.D.
Rosandra N. Kaplan, M.D.
Tatiana S. Karpova, Ph.D.
Mikhail Kashlev, Ph.D.
Mary F. Kearney, Ph.D.
Jonathan R. Keller, Ph.D.
Jairaj K. Acharya, MBBS, Ph.D.
Sankar Adhya, Ph.D.
Mirit I. Aladjem, Ph.D.
Christine Campo Alewine, M.D., Ph.D.
Stefan Ambs, Ph.D., M.P.H.
Suresh V. Ambudkar, Ph.D.
Ping An, M.D., MPH
Stephen K. Anderson, Ph.D.
Christina M. Annunziata, M.D., Ph.D.
Peter D. Aplan, M.D.
Andrea B. Apolo, M.D.
Ettore Appella, M.D.
Evgeny Arons, Ph.D.
Jonathan D. Ashwell, M.D.
Yawen Bai, Ph.D.
Lakshmi Balagopalan, Ph.D.
Joseph J. Barchi Jr., Ph.D.
Frederic G. Barr, M.D., Ph.D.
Valarie A. Barr, Ph.D.
Munira A. Basrai, Ph.D.
Thomas R. Bauer Jr., Ph.D.
Tapan K. Bera, Ph.D
Cristina Bergamaschi, Ph.D.
Jay A. Berzofsky, M.D., Ph.D.
John A. Beutler, Ph.D.
Robert Blumenthal, Ph.D.
William M. Bonner, Ph.D.
Remy Bosselut, M.D., Ph.D.
Donald P. Bottaro, Ph.D.
Martin W. Brechbiel, Ph.D.
Christopher B. Buck, Ph.D.
Anuradha S. Budhu, Ph.D.
Minh Bui, Ph.D.
Terrence R. Burke Jr., Ph.D.
Michael Bustin, Ph.D.
R. Andrew Byrd, Ph.D.
Kevin A. Camphausen, M.D.
Liang Cao, Ph.D.
Natasha J. Caplen, Ph.D.
Mary N. Carrington, Ph.D.
Rafael Casellas, Ph.D.
Christophe Cataisson, Ph.D.
Dhruba K. Chattoraj, Ph.D.
Jianbo Chen, Ph.D.
Sheue-yann Cheng, Ph.D.
Y.S. Robert Cheng, D.V.M., Ph.D.
Murali Krishna Cherukuri, Ph.D.
Yungping (Jeffrey) Chiang, Ph.D.
Swati S. Choksi, Ph.D.
Peter L. Choyke, M.D., F.A.C.R.
Deborah E. Citrin, M.D.
C. Norman Coleman, M.D.
Kevin C. Conlon, M.D.
Donald L. Court, Ph.D.
Ira O. Daar, Ph.D.
William L. Dahut, M.D.
Yamini Dalal, Ph.D.
David N. Danforth Jr., M.S., M.D.
Debananda Das, Ph.D.
Siddhartha A.K. Datta, Ph.D.
Zbigniew Dauter, Ph.D.
David A. Davis, Ph.D.
Chi-Ping Day, Ph.D.
Patricia M. Day, Ph.D.
Krista A. Frankenberry, Ph.D.
Nallathamby Devasahayam, B.S.
James H. Doroshow, M.D.
Shannon M. Doyle, Ph.D.
Sigrid P. Dubois, Ph.D.
Our Clinical Director Team
Immune Deficiency Cellular Therapy Program
Laboratory of Cancer Immunometabolism
Laboratory of Integrative Cancer Immunology
News & Events
Women's Malignancies Branch
Surgical Oncology Program
Thoracic and GI Malignancies Branch
Cancer Data Science Laboratory
Office of Scientific Programs
Office of Research Operations and Planning
Office of Translational Resources
Genitourinary Malignancies Branch
Office of Research Support at CCR
Thoracic Surgery Branch
Urologic Oncology Branch
Neuro-Oncology Branch
Pediatric Oncology Branch
Animal Resource Program
Basic Research Laboratory
Cancer and Developmental Biology Laboratory
Chemical Biology Laboratory
Developmental Therapeutics Branch
Experimental Immunology Branch
Experimental Transplantation and Immunotherapy Branch
RNA Biology Laboratory
Genetics Branch
HIV and AIDS Malignancy Branch
Host-Virus Interaction Branch
Retroviral Replication Laboratory
HIV Dynamics and Replication Program
Laboratory of Biochemistry and Molecular Biology
Laboratory of Cancer Biology and Genetics
Laboratory of Cell and Developmental Signaling
Laboratory of Cell Biology
Laboratory of Cellular and Molecular Biology
Laboratory of Cellular Oncology
Laboratory of Genitourinary Cancer Pathogenesis
Laboratory of Genome Integrity
Laboratory of Human Carcinogenesis
Laboratory of Immune Cell Biology
Laboratory of Metabolism
Laboratory of Molecular Biology
Laboratory of Pathology
Laboratory of Protein Dynamics and Signaling
Laboratory of Receptor Biology and Gene Expression
Laboratory of Tumor Immunology and Biology
Lymphoid Malignancies Branch
Macromolecular Crystallography Laboratory
Molecular Imaging Branch
Molecular Targets Program
Mouse Cancer Genetics Program
Radiation Biology Branch
Radiation Oncology Branch
Structural Biophysics Laboratory
Surgery Branch
Vaccine Branch
Office of the Clinical Director
Office of the Director